<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Non‐nutritive sweeteners for diabetes mellitus - Lohner, S - 2020 | Cochrane Library</title> <meta content="Non‐nutritive sweeteners for diabetes mellitus - Lohner, S - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012885.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Non‐nutritive sweeteners for diabetes mellitus - Lohner, S - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012885.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD012885.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Non‐nutritive sweeteners for diabetes mellitus" name="citation_title"/> <meta content="Szimonetta Lohner" name="citation_author"/> <meta content="University of Pécs" name="citation_author_institution"/> <meta content="lohner.szimonetta@pte.hu" name="citation_author_email"/> <meta content="Daniela Kuellenberg de Gaudry" name="citation_author"/> <meta content="Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg" name="citation_author_institution"/> <meta content="Ingrid Toews" name="citation_author"/> <meta content="Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg" name="citation_author_institution"/> <meta content="Tamas Ferenci" name="citation_author"/> <meta content="Obuda University" name="citation_author_institution"/> <meta content="Joerg J Meerpohl" name="citation_author"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD012885.pub2" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/05/25" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012885.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012885.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD012885.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Bias; Body Weight; Diabetes Mellitus, Type 1 [blood, complications, *diet therapy]; Diabetes Mellitus, Type 2 [blood, complications, *diet therapy]; Glycated Hemoglobin [analysis]; Non-Nutritive Sweeteners [*administration &amp; dosage, adverse effects]; Nutritive Sweeteners [administration &amp; dosage]; Placebos [therapeutic use]; Quality of Life; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD012885.pub2&amp;doi=10.1002/14651858.CD012885.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="23LRTUA6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD012885\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD012885\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANS","zh_HANT","ru","ko","th","ms","ja","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD012885.pub2",title:"Non\\u2010nutritive sweeteners for diabetes mellitus",firstPublishedDate:"May 25, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Metabolic and Endocrine Disorders Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012885.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012885.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD012885.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD012885.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012885.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD012885.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;บทคัดย่อ&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Zusammenfassung in einfacher Sprache&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;th&quot;,&quot;title&quot;:&quot;ข้้อสรุปภาษาธรรมดา&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD012885.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD012885.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD012885.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD012885.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>13684 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD012885.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-sec-0136"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-sec-0015"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-sec-0016"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-sec-0055"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-sec-0130"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/appendices#CD012885-sec-0141"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/table_n/CD012885StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/table_n/CD012885StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Non‐nutritive sweeteners for diabetes mellitus</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#CD012885-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Szimonetta Lohner</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#CD012885-cr-0005">Daniela Kuellenberg de Gaudry</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#CD012885-cr-0006">Ingrid Toews</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#CD012885-cr-0007">Tamas Ferenci</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information#CD012885-cr-0008">Joerg J Meerpohl</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information/en#CD012885-sec-0163">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 25 May 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD012885.pub2">https://doi.org/10.1002/14651858.CD012885.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD012885-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012885-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012885-abs-0003">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012885-abs-0019">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012885-abs-0015">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012885-abs-0017">Français</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012885-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/th#CD012885-abs-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012885-abs-0005">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD012885-abs-0001" lang="en"> <section id="CD012885-sec-0001"> <h3 class="title" id="CD012885-sec-0001">Background</h3> <p>Products sweetened with non‐nutritive sweeteners (NNS) are widely available. Many people with type 1 or type 2 diabetes use NNS as a replacement for nutritive sweeteners to control their carbohydrate and energy intake. Health outcomes associated with NNS use in diabetes are unknown. </p> </section> <section id="CD012885-sec-0002"> <h3 class="title" id="CD012885-sec-0002">Objectives</h3> <p>To assess the effects of non‐nutritive sweeteners in people with diabetes mellitus.</p> </section> <section id="CD012885-sec-0003"> <h3 class="title" id="CD012885-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid, Scopus, the WHO ICTRP, and ClinicalTrials.gov. The date of the last search of all databases (except for Scopus) was May 2019. We last searched Scopus in January 2019. We did not apply any language restrictions. </p> </section> <section id="CD012885-sec-0004"> <h3 class="title" id="CD012885-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) with a duration of four weeks or more comparing any type of NNS with usual diet, no intervention, placebo, water, a different NNS, or a nutritive sweetener in individuals with type 1 or type 2 diabetes. Trials with concomitant behaviour‐changing interventions, such as diet, exercise, or both, were eligible for inclusion, given that the concomitant interventions were the same in the intervention and comparator groups. </p> </section> <section id="CD012885-sec-0005"> <h3 class="title" id="CD012885-sec-0005">Data collection and analysis</h3> <p>Two review authors independently screened abstracts, full texts, and records retrieved from trials registries, assessed the certainty of the evidence, and extracted data. We used a random‐effects model to perform meta‐analysis, and calculated effect estimates as risk ratios (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes, using 95% confidence intervals (CIs). We assessed risk of bias using the Cochrane 'Risk of bias' tool and the certainty of evidence using the GRADE approach. </p> </section> <section id="CD012885-sec-0006"> <h3 class="title" id="CD012885-sec-0006">Main results</h3> <p>We included nine RCTs that randomised a total of 979 people with type 1 or type 2 diabetes. The intervention duration ranged from 4 to 10 months. We judged none of these trials as at low risk of bias for all ’Risk of bias’ domains; most of the included trials did not report the method of randomisation. </p> <p>Three trials compared the effects of a dietary supplement containing NNS with sugar: glycosylated haemoglobin A1c (HbA1c) was 0.4% higher in the NNS group (95% CI −0.5 to 1.2; P = 0.44; 3 trials; 72 participants; very low‐certainty evidence). The MD in weight change was −0.1 kg (95% CI −2.7 to 2.6; P = 0.96; 3 trials; 72 participants; very low‐certainty evidence). None of the trials with sugar as comparator reported on adverse events. </p> <p>Five trials compared NNS with placebo. The MD for HbA1c was 0%, 95% CI −0.1 to 0.1; P = 0.99; 4 trials; 360 participants; very low‐certainty evidence. The 95% prediction interval ranged between −0.3% and 0.3%. The comparison of NNS versus placebo showed a MD in body weight of −0.2 kg, 95% CI −1 to 0.6; P = 0.64; 2 trials; 184 participants; very low‐certainty evidence. Three trials reported the numbers of participants experiencing at least one non‐serious adverse event: 36/113 participants (31.9%) in the NNS group versus 42/118 participants (35.6%) in the placebo group (RR 0.78, 95% CI 0.39 to 1.56; P = 0.48; 3 trials; 231 participants; very low‐certainty evidence). </p> <p>One trial compared NNS with a nutritive low‐calorie sweetener (tagatose). HbA1c was 0.3% higher in the NNS group (95% CI 0.1 to 0.4; P = 0.01; 1 trial; 354 participants; very low‐certainty evidence). This trial did not report body weight data and adverse events. </p> <p>The included trials did not report data on health‐related quality of life, diabetes complications, all‐cause mortality, or socioeconomic effects. </p> </section> <section id="CD012885-sec-0007"> <h3 class="title" id="CD012885-sec-0007">Authors' conclusions</h3> <p>There is inconclusive evidence of very low certainty regarding the effects of NNS consumption compared with either sugar, placebo, or nutritive low‐calorie sweetener consumption on clinically relevant benefit or harm for HbA1c, body weight, and adverse events in people with type 1 or type 2 diabetes. Data on health‐related quality of life, diabetes complications, all‐cause mortality, and socioeconomic effects are lacking. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD012885-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD012885-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD012885-abs-0004">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD012885-abs-0020">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD012885-abs-0016">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD012885-abs-0018">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD012885-abs-0014">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD012885-abs-0010">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD012885-abs-0013">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD012885-abs-0008">Русский</a> </li> <li class="section-language"> <a class="" href="full/th#CD012885-abs-0012">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD012885-abs-0006">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD012885-abs-0007">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD012885-abs-0002" lang="en"> <h3>Non‐nutritive sweeteners for diabetes mellitus</h3> <p><b>Review question</b> </p> <p>Are non‐nutritive sweeteners beneficial or harmful in people with diabetes?</p> <p><b>Background</b> </p> <p>Non‐nutritive sweeteners are sweetening agents having higher sweetening intensity and lower calorie content per gram compared to caloric sweeteners like sucrose or corn syrups. Both the general population and diabetic people use non‐nutritive sweeteners as a caloric sweetener replacement to control their carbohydrate and energy intake. Most of the non‐nutritive sweeteners approved for human consumption are synthetic (artificial sweeteners); however, increasing numbers of natural non‐caloric sweeteners are becoming available for human consumption. Products sweetened with non‐nutritive sweeteners are widely available on the market: diet beverages, diet yoghourts, desserts, and chewing gums are the most common products containing non‐nutritive sweeteners. Non‐nutritive sweeteners are also available as table‐top sweeteners for use by consumers at home as a sweetening agent for beverages and for cooking and baking. </p> <p>There is very little information about the health consequences of this intensified non‐nutritive sweeteners consumption in people with diabetes. We wanted to find out whether non‐nutritive sweeteners consumption in people with diabetes has an effect on long‐term average blood sugar levels (glycosylated haemoglobin A1c ‐ HbA1c), body weight, side effects, diabetes complications (such as heart attack, eye or kidney disease), and health‐related quality of life. </p> <p><b>Study characteristics</b> </p> <p>We found nine randomised controlled trials (studies in which participants are assigned to one of two or more treatment groups using a random method) that allocated people with diabetes to either a group that received a non‐nutritive sweetener or a comparator group. The comparator was usual diet with additional sugar in three studies; placebo (a dummy pill) in five studies; and tagatose (a nutritive low‐calorie sweetener) in one study. The studies included a total of 979 participants; most of the studies were small, with fewer than 100 participants. The length of the studies varied from 4 to 10 months. </p> <p>This evidence is up‐to‐date as of May 2019.</p> <p><b>Key results</b> </p> <p>Data on health‐related quality of life, diabetes complications, death from any cause, and socioeconomic effects (such as absence from work, visits to general practitioner, medication consumption) were lacking, and data were generally sparse for all comparisons. The available data did not show a clear difference between non‐nutritive sweeteners and sugar, placebo, or the nutritive low‐calorie sweetener tagatose for HbA1c, body weight, and side effects. </p> <p><b>Certainty of the evidence</b> </p> <p>We rated the overall certainty of the evidence as very low, mainly due to the small numbers of included studies and participants and methodological limitations of the included studies. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD012885-sec-0136" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD012885-sec-0136"></div> <h3 class="title" id="CD012885-sec-0137">Implications for practice</h3> <section id="CD012885-sec-0137"> <p>There is no firm evidence as to whether non‐nutritive sweeteners compared with any other type of dietary intervention (including sugar, placebo, or nutritive, low‐calorie sweeteners) have substantial effects on health outcomes. Data on patient‐important outcomes such as adverse events, diabetes complications, health‐related quality of life, and socioeconomic effects are scarce or lacking. </p> </section> <h3 class="title" id="CD012885-sec-0138">Implications for research</h3> <section id="CD012885-sec-0138"> <p>It remains to be determined whether there are any substantial beneficial or harmful effects of consuming non‐nutritive sweeteners in people with type 1 or type 2 diabetes mellitus. There is a need for further long‐term randomised controlled trials conducted with rigorous methodology, with large sample size that are investigating patient‐relevant endpoints (especially adverse events, diabetes complications, health‐related quality of life, and socioeconomic effects). </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD012885-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD012885-sec-0008"></div> <div class="table" id="CD012885-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Non‐nutritive sweeteners for diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Non‐nutritive sweeteners compared with sucrose, placebo, or a nutritive, low‐calorie sweetener for diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> people with diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> non‐nutritive sweeteners (aspartame, rebaudioside A, saccharin, sodium‐cyclamate, sucralose, steviol glycoside) </p> <p><b>Comparison:</b> sucrose; placebo; nutritive, low‐calorie sweetener (tagatose) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes/Comparisions</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator<br/>(sucrose; placebo; nutritive, low‐calorie sweetener)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Non‐nutritive sweeteners<br/>(aspartame, rebaudioside A, saccharin, sodium‐cyclamate, sucralose, steviol glycoside)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Health‐related quality of life</b> </p> </th> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Diabetes complications</b> </p> </th> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality</b> </p> </th> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Non‐serious adverse events (N)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus sugar</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus placebo</b> </p> <p>NNS: aspartame, rebaudioside A, steviol glycoside</p> <p>Follow‐up: 16 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> (139 to 555) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (0.39 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus nutritive, low‐calorie sweetener</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>HbA1c (%)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus sugar</b> </p> <p>NNS: aspartame, saccharin, sodium‐cyclamate</p> <p>Follow‐up: 4 to 6 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c ranged across control groups from <b>6.8% to 7.5%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the NNS group was <b>0.4% higher</b> (0.5% lower to 1.2% higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus placebo</b> </p> <p>NNS: aspartame, rebaudioside A, steviol glycoside</p> <p>Follow‐up: 13 to 16 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final HbA1c ranged across control groups from <b>7.3% to 11.4%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the NNS and placebo groups <b>did not differ</b> (MD 0%, −0.1% lower to 0.1% higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>c</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged between −0.3% and 0.3%</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus nutritive, low‐calorie sweetener (tagatose)</b> </p> <p>NNS: sucralose</p> <p>Follow‐up: 16 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the control group was <b>7.3%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the NNS group was <b>0.3% higher</b> (0.1% higher to 0.4% higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>d</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Body weight (kg)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus sugar</b> </p> <p>NNS: aspartame, saccharin, sodium‐cyclamate</p> <p>Follow‐up: 4 to 6 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the control groups was <b>66.8 kg to 75.9 kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the intervention groups was <b>0.1 kg lower</b> (2.7 kg lower to 2.6 kg higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>e</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus placebo</b> </p> <p>NNS: aspartame, rebaudioside A</p> <p>Follow‐up: 12 to 16 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final body weight ranged across control groups from to <b>79.4 to 98.4 kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the intervention groups was <b>0.2 kg lower</b> (1 kg lower to 0.6 kg higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>f</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus nutritive, low‐calorie sweetener</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Socioeconomic effects</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>MD:</b> mean difference; <b>NNS:</b> non‐nutritive sweetener; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level because of inconsistency (no consistent direction of effect) and two levels because of serious imprecision (CI consistent with benefit and harm, small sample size, and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0159">Appendix 18</a>.<br/><sup>b</sup>Downgraded by one level because of inconsistency (point estimates varied widely, not all CIs overlapped, no consistent direction of effect); one level because of indirectness (surrogate outcome, insufficient time frame); and one level because of serious imprecision (CI consistent with benefit and harm, small sample size, and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0158">Appendix 17</a>.<br/><sup>c</sup>Downgraded by one level because of indirectness (surrogate outcome) and two levels because of serious imprecision (small sample size and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0159">Appendix 18</a>.<br/><sup>d</sup>Downgraded by one level because of risk of bias (attrition bias and selective reporting); one level because of indirectness (surrogate outcome); and one level because of imprecision (small number of included studies) ‐ see <a href="./appendices#CD012885-sec-0160">Appendix 19</a>.<br/><sup>e</sup>Downgraded by one level because of inconsistency (no consistent direction of effect) and two levels because of serious imprecision (CI consistent with benefit and harm, small sample size, and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0158">Appendix 17</a>.<br/><sup>f</sup>Downgraded by one level because of risk of bias (selective reporting) and two levels because of serious imprecision (small sample size and small number of included studies) ‐ see <a href="./appendices#CD012885-sec-0159">Appendix 18</a>. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD012885-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD012885-sec-0009"></div> <section id="CD012885-sec-0010"> <h3 class="title" id="CD012885-sec-0010">Description of the condition</h3> <p>Diabetes mellitus is a metabolic disorder impeding the pancreas from producing enough insulin, body cells from responding properly to the insulin produced, or both. This leads to chronic hyperglycaemia (i.e. elevated plasma glucose levels) and disturbances of carbohydrate, fat, and protein metabolism. In the long term, this condition leads to complications such as retinopathy, nephropathy, neuropathy, and an increased risk for cardiovascular diseases. </p> <p>Diabetes is one of the most common diseases in the world, and its burden is increasing continuously: the global prevalence of diabetes in adults over 18 years of age was 8.5% in 2014 (<a href="./references#CD012885-bbs2-0162" title="World Health Organization. Diabetes. Fact Sheet (Reviewed November 2016). www.who.int/mediacentre/factsheets/fs312/en (accessed 5 January 2017).">WHO 2016</a>). Diabetes was the direct cause of 1.5 million deaths in 2012 (<a href="./references#CD012885-bbs2-0162" title="World Health Organization. Diabetes. Fact Sheet (Reviewed November 2016). www.who.int/mediacentre/factsheets/fs312/en (accessed 5 January 2017).">WHO 2016</a>). The global cost of diabetes was about USD 825,000 million per year in 2016 (<a href="./references#CD012885-bbs2-0147" title="NCD Risk Factor Collaboration. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet2016;387:1513-30.">NCD‐RisC 2016</a>). </p> <p>A healthy diet, regular physical activity, and pharmacotherapy are key components of diabetes management. For many individuals with diabetes, the most challenging part of the treatment plan is determining what to eat. </p> <p>Today, nutrition therapy is recommended for all people with type 1 and type 2 diabetes as a component of their overall treatment plan (<a href="./references#CD012885-bbs2-0115" title="EvertAB , BoucherJL , CypressM , DunbarSA , FranzMJ , Mayer-DavisEJ , et al, American Diabetes Association. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care2013;36(11):3821-42.">Evert 2013</a>). The goals of nutrition therapy are to promote and support healthy eating patterns with a variety of nutrient‐dense foods in appropriate portion size to achieve individualised glycaemic, blood pressure, and lipid goals; attain and maintain body weight goals; and delay or prevent complications of diabetes. A further goal is to maintain the pleasure of eating by providing positive messages about food choices and practical tools for day‐to‐day meal planning (<a href="./references#CD012885-bbs2-0115" title="EvertAB , BoucherJL , CypressM , DunbarSA , FranzMJ , Mayer-DavisEJ , et al, American Diabetes Association. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care2013;36(11):3821-42.">Evert 2013</a>). </p> </section> <section id="CD012885-sec-0011"> <h3 class="title" id="CD012885-sec-0011">Description of the intervention</h3> <p>Non‐nutritive sweeteners (NNS) are defined as sweetening agents having higher sweetening intensity and lower calorie content per gram compared to caloric sweeteners like sucrose or corn syrups (<a href="./references#CD012885-bbs2-0106" title="ChattopadhyayS , RaychaudhuriU , ChakrabortyR . Artificial sweeteners - a review. Journal of Food Science and Technology2014;51(4):611-21.">Chattopadhyay 2014</a>). Both the general population and individuals with type 1 or type 2 diabetes use NNS as a caloric sweetener replacement to control their carbohydrate and energy intake. </p> <p>Most of the NNS approved for human consumption are synthetic (artificial sweeteners); however, increasing numbers of natural non‐caloric sweeteners are becoming available for human consumption. </p> <p>Products sweetened with NNS are widely available on the market: diet beverages, diet yoghourts, desserts, and chewing gums are the most common products with NNS. NNS are also available as table‐top sweeteners for use by consumers at home as a sweetening agent for beverages and for cooking and baking. </p> <p>With regard to the range of approved artifical sweeteners, there are important differences amongst countries. In the USA, the Food and Drug Administration (FDA) has to date approved six artificial sweeteners for human consumption: acesulfame‐K, aspartame, neotame, saccharin, sucralose, and advantame. Additionally, steviol glycosides, thaumatin, and luo han guo fruit extracts (mogrosides) are approved NNS of natural origin (<a href="./references#CD012885-bbs2-0117" title="US Food and Drug Administration. High-intensity sweeteners. www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397716.htm (accessed 26 January 2017).">FDA 2015a</a>). In the European Union, the following 11 NNS are approved for use in foods and drinks by the European Food Safety Authority: acesulfame‐K (E950), advantame (E969), aspartame (E951), aspartame‐acesulfame salt (E962), cyclamate (E952), neohesperidine DC (E959), neotame (E961), saccharin (E954), steviol glycosides (E960), sucralose (E955), and thaumatin (E957) (<a href="./references#CD012885-bbs2-0121" title="Food Standards Agency. Current EU approved additives and their E numbers. www.food.gov.uk/science/additives/enumberlist#toc-4 (accessed 26 January 2017).">FSA 2016</a>). </p> <p>Approved NNS are described in more detail below. <a href="#CD012885-tbl-0002">Table 1</a> lists the acceptable daily intake levels defined by the main regulatory bodies (<a href="./references#CD012885-bbs2-0136" title="World Health Organization. Evaluations of the Joint FAO/WHO expert committee on food additives. apps.who.int/food-additives-contaminants-jecfa-database/search.aspx?fcc=1 (accessed 26 January 2017).">JECFA 2010</a>). </p> <div class="table" id="CD012885-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Acceptable daily intake levels of non‐nutritive sweeteners as defined by regulatory bodies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sweetener</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>FDA (mg/kg body weight) (</b><a href="./references#CD012885-bbs2-0117" title="US Food and Drug Administration. High-intensity sweeteners. www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397716.htm (accessed 26 January 2017)."><b>FDA 2015a</b> </a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SCF/EFSA (mg/kg body weight) (</b><a href="./references#CD012885-bbs2-0145" title="MortensenA . Sweeteners permitted in the European Union: safety aspects. Scandinavian Journal of Food and Nutrition2006;50(3):104-16."><b>Mortensen 2006</b> </a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>JECFA (mg/kg body weight) (</b><a href="./references#CD012885-bbs2-0136" title="World Health Organization. Evaluations of the Joint FAO/WHO expert committee on food additives. apps.who.int/food-additives-contaminants-jecfa-database/search.aspx?fcc=1 (accessed 26 January 2017)."><b>JECFA 2010</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACE‐K</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advantame</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspartame</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclamate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not approved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Luo han guo fruit extracts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neohesperidine DC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not approved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neotame</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saccharin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sucralose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steviol glycosides</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thaumatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not approved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><b>ACE‐K</b> : acesulfame potassium; <b>DC</b> : dihydrochalcone; <b>EFSA</b> : European Food Safety Authority;<b>FDA</b> : US Food and Drug Administration; <b>JECFA</b> : Joint FAO/WHO Expert Committee on Food Additives; <b>SCF</b>: Scientific Committee on Food (European Commission). </p> </div> </div> <p><b>Acesulfame</b> ‐<b>K</b> (acesulfame potassium) is a combination of an organic acid and potassium and was first approved for general use as an NNS in 1988. It contains 0 kilocalories (kcal)/g and is 200 times sweeter than sucrose (<a href="./references#CD012885-bbs2-0106" title="ChattopadhyayS , RaychaudhuriU , ChakrabortyR . Artificial sweeteners - a review. Journal of Food Science and Technology2014;51(4):611-21.">Chattopadhyay 2014</a>). The estimated daily intake (EDI; i.e. the presumed daily consumption of NNS) ranges from 0.2 to 1.7 mg/kg of body weight (<a href="./references#CD012885-bbs2-0119" title="FitchC , KeimKS , Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. Journal of the Academy of Nutrition and Dietetics2012;112(5):739-58.">Fitch 2012</a>; <a href="./references#CD012885-bbs2-0123" title="GardnerC , Wylie-RosettJ , GiddingSS , SteffenLM , JohnsonRK , ReaderD , et al, American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, American Diabetes Association. Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care2012;35(8):1798-808.">Gardner 2012</a>). </p> <p><b>Advantame</b> is an N‐substituted derivative of aspartame made from aspartame and vanillin (<a href="./references#CD012885-bbs2-0148" title="OtabeA , FujiedaT , MasuyamaT , UbukataK , LeeC . Advantame - an overview of the toxicity data. Food and Chemical Toxicology2011;49(Suppl 1):S2-7.">Otabe 2011</a>). It is approximately 20,000 times sweeter than sucrose (<a href="./references#CD012885-bbs2-0117" title="US Food and Drug Administration. High-intensity sweeteners. www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397716.htm (accessed 26 January 2017).">FDA 2015a</a>). </p> <p><b>Aspartame</b> is the methyl ester of the dipeptide of the amino acids aspartic acid and the essential amino acid phenylalanine. It was approved for general use in 1981 and is 180 to 200 times sweeter than sucrose (<a href="./references#CD012885-bbs2-0106" title="ChattopadhyayS , RaychaudhuriU , ChakrabortyR . Artificial sweeteners - a review. Journal of Food Science and Technology2014;51(4):611-21.">Chattopadhyay 2014</a>). Although it has 4 kcal/g, the intensity of sweet taste means that very small amounts are required to achieve desired sweetness levels. The EDI ranges from 0.2 to 4.1 mg/kg of body weight (<a href="./references#CD012885-bbs2-0119" title="FitchC , KeimKS , Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. Journal of the Academy of Nutrition and Dietetics2012;112(5):739-58.">Fitch 2012</a>; <a href="./references#CD012885-bbs2-0123" title="GardnerC , Wylie-RosettJ , GiddingSS , SteffenLM , JohnsonRK , ReaderD , et al, American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, American Diabetes Association. Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care2012;35(8):1798-808.">Gardner 2012</a>). </p> <p><b>Cyclamate</b> (cyclamic acid) is used as an NNS in two forms: sodium cyclamate and calcium cyclamate. It is 30 times sweeter than sucrose and contains zero calories (<a href="./references#CD012885-bbs2-0106" title="ChattopadhyayS , RaychaudhuriU , ChakrabortyR . Artificial sweeteners - a review. Journal of Food Science and Technology2014;51(4):611-21.">Chattopadhyay 2014</a>). It is used in more than 50 countries (<a href="./references#CD012885-bbs2-0119" title="FitchC , KeimKS , Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. Journal of the Academy of Nutrition and Dietetics2012;112(5):739-58.">Fitch 2012</a>); however, cyclamate and its salts are currently prohibited from use in the USA (<a href="./references#CD012885-bbs2-0117" title="US Food and Drug Administration. High-intensity sweeteners. www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397716.htm (accessed 26 January 2017).">FDA 2015a</a>). </p> <p><b>Luo han guo</b> (also known as <i>Siraitia grosvenori</i>) fruit extract is a traditional Chinese herb containing varying levels of mogrosides. Depending on the mogroside content, it is reported to be 100 to 250 times sweeter than sucrose (<a href="./references#CD012885-bbs2-0117" title="US Food and Drug Administration. High-intensity sweeteners. www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397716.htm (accessed 26 January 2017).">FDA 2015a</a>). </p> <p><b>Neohesperidine dihydrochalcone (DC)</b> is a non‐nutritive sweetener derived from the flavones of citrus fruit. The customary concentration is 400 to 600 times sweeter than sucrose. </p> <p><b>Neotame</b> is a dipeptide methyl ester derivate. It has a sweetness factor approximately 7000 to 13,000 times greater than that of sucrose and approximately 30 to 60 times greater than that of aspartame, depending on the food application (<a href="./references#CD012885-bbs2-0097" title="AguilarF , AutrupH , BarlowS , CastleL , CrebelliR , DekantW , et al. Neotame as a sweetener and flavour enhancer. Scientific opinion of the panel on food additives, flavourings, processing aids and materials in contact with food. EFSA Journal2007;581:1-43.">Aguilar 2007</a>). </p> <p><b>Saccharin</b> is the oldest NNS, first discovered and used in 1879 (<a href="./references#CD012885-bbs2-0118" title="US Food and Drug Administration. Additional information about high-intensity sweeteners permitted for use in food in the United States. www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397725.htm (accessed 19 October 2017).">FDA 2015b</a>). It is an organic chemical compound (O‐sulfobenzimide) that can be artificially synthesised in various ways. It has no calories and is about 300 times sweeter than sucrose (<a href="./references#CD012885-bbs2-0106" title="ChattopadhyayS , RaychaudhuriU , ChakrabortyR . Artificial sweeteners - a review. Journal of Food Science and Technology2014;51(4):611-21.">Chattopadhyay 2014</a>); however, it has an unpleasant bitter or metallic aftertaste. The EDI ranges from 0.1 to 2.0 mg/kg of body weight (<a href="./references#CD012885-bbs2-0119" title="FitchC , KeimKS , Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. Journal of the Academy of Nutrition and Dietetics2012;112(5):739-58.">Fitch 2012</a>). </p> <p><i><b>Stevia rebaudiana</b> </i> ‐based products are the best‐known NNS of natural origin. Steviol glycosides, extracted from the plant stevia, contain stevioside and rebaudioside A as well as other glycosides (<a href="./references#CD012885-bbs2-0105" title="CeunenS , GeunsJM . Steviol glycosides: chemical diversity, metabolism, and function. Journal of Natural Products2013;76(6):1201-28.">Ceunen 2013</a>). Steviol glycosides are 10 to 15 times sweeter than sucrose. Stevia has been used as a sweetener in some countries (e.g. Japan) for decades, whilst it was approved as a food additive by the European Food Safety Authority in 2011 (<a href="./references#CD012885-bbs2-0114" title="European Commission. Commission regulation (EU) No 1131/2011 of 11 November 2011 amending annex II to regulation (EC) No 1333/2008 of the European Parliament and of the council with regard to steviol glycosides. eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2011:295:0205:0211:EN:PDF (accessed 19 October 2017).">EC 2011</a>).The FDA first recognised the use of certain steviol glycosides as a sweetener as generally safe in 2008 (<a href="./references#CD012885-bbs2-0116" title="US Food and Drug Administration. Agency response letter GRAS notice no. GRN 000252. www.fda.gov/Food/IngredientsPackagingLabeling/GRAS/NoticeInventory/ucm154988.htm (accessed 19 October 2017).">FDA 2008</a>). </p> <p><b>Sucralose</b> is an organic chemical compound (trichlorosucrose) that has been approved for general use as a non‐nutritive sweetener since 1999 (<a href="./references#CD012885-bbs2-0123" title="GardnerC , Wylie-RosettJ , GiddingSS , SteffenLM , JohnsonRK , ReaderD , et al, American Heart Association Nutrition Committee of the Council on Nutrition, Physical Activity and Metabolism, Council on Arteriosclerosis, Thrombosis and Vascular Biology, Council on Cardiovascular Disease in the Young, American Diabetes Association. Nonnutritive sweeteners: current use and health perspectives: a scientific statement from the American Heart Association and the American Diabetes Association. Diabetes Care2012;35(8):1798-808.">Gardner 2012</a>). It is 450 to 650 times sweeter than sucrose and has 0 kcal/g. The quality and intensity of sweet taste is very close to that of sucrose (<a href="./references#CD012885-bbs2-0106" title="ChattopadhyayS , RaychaudhuriU , ChakrabortyR . Artificial sweeteners - a review. Journal of Food Science and Technology2014;51(4):611-21.">Chattopadhyay 2014</a>). The EDI ranges from 0.1 to 2.0 mg/kg of body weight (<a href="./references#CD012885-bbs2-0119" title="FitchC , KeimKS , Academy of Nutrition and Dietetics. Position of the Academy of Nutrition and Dietetics: use of nutritive and nonnutritive sweeteners. Journal of the Academy of Nutrition and Dietetics2012;112(5):739-58.">Fitch 2012</a>). </p> <p><b>Thaumatin</b> is a mixture of sweet‐tasting polypeptides that can be extracted from the skin surrounding the seeds of the West African katemfe fruit. </p> <section id="CD012885-sec-0012"> <h4 class="title">Adverse effects of the intervention</h4> <p>Food safety agencies consider consumption of NNS up to the acceptable daily intake to be safe; however, the effects of NNS on glucose metabolism are not clearly understood (<a href="./references#CD012885-bbs2-0153" title="Romo-RomoA , Aguilar-SalinasCA , Brito-CórdovaGX , Gómez DíazRA , Vilchis ValentínD , Almeda-ValdesP . Effects of the non-nutritive sweeteners on glucose metabolism and appetite regulating hormones: systematic review of observational prospective studies and clinical trials. PLOS ONE2016;18(11):e0161264.">Romo‐Romo 2016</a>). Individuals with diabetes may consume NNS for very long periods (i.e. years or even decades) on a daily basis, possibly at an amount exceeding the acceptable daily intake levels (<a href="./references#CD012885-bbs2-0133" title="IlbäckNG , AlzinM , JahrlS , Enghardt-BarbieriH , BuskL . Estimated intake of the artificial sweeteners acesulfame-K, aspartame, cyclamate and saccharin in a group of Swedish diabetics. Food Additives and Contaminants2003;20(2):99-114.">Ilbäck 2003</a>). There has been little research on the negative health outcomes arising as a consequence of consuming such considerable amounts of NNS over long periods, and even less focusing specifically on people with diabetes. </p> <p>A potentially increased risk for cancer is a starting point for many debates around the safety of NNS (<a href="./references#CD012885-bbs2-0122" title="GallusS , ScottiL , NegriE , TalaminiR , FranceschiS , MontellaM , et al. Artificial sweeteners and cancer risk in a network of case–control studies. Annals of Oncology2007;18:40-4.">Gallus 2007</a>). </p> <p>Additionally, some studies indicated that NNS consumption might lead to weight gain instead of the expected weight loss (<a href="./references#CD012885-bbs2-0143" title="MattesRD , PopkinBM . Nonnutritive sweetener consumption in humans: effects on appetite and food intake and their putative mechanisms. American Journal of Clinical Nutrition2009;89(1):1-14.">Mattes 2009</a>), which in people with diabetes could lead to the worsening of glycaemic control, blood pressure, and lipid profile (<a href="./references#CD012885-bbs2-0096" title="American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Diabetes Care2016;39(Suppl 1):S47–51.">ADA 2016</a>). </p> <p>Furthermore, some researchers have also questioned whether NNS (consumed without caloric sweeteners) could enhance the cephalic phase of insulin secretion (the early increase of insulin secretion immediately following gustatory stimulation, prior to the rise of blood glucose) by evoking the recognition of the sweet taste, sight, smell, and expectation of food, and whether in the absence of caloric sweetener intake it could lead to exercise‐induced hypoglycaemia (<a href="./references#CD012885-bbs2-0024" title="FerlandA , BrassardP , PoirierP . Is aspartame really safer in reducing the risk of hypoglycemia during exercise in patients with type 2 diabetes?Diabetes Care2007;30(7):e59. ">Ferland 2007</a>; <a href="./references#CD012885-bbs2-0138" title="JustT , PauHW , EngelU , HummelT . Cephalic phase insulin release in healthy humans after taste stimulation?Appetite2008;51(3):622-7.">Just 2008</a>). </p> <p>A systematic review and dose‐response meta‐analysis of prospective studies found a positive association between artificially sweetened soft drink intake and type 2 diabetes risk (<a href="./references#CD012885-bbs2-0124" title="GreenwoodDC , ThreapletonDE , EvansCEL , CleghornCL , NykjaerC , WoodheadC , et al. Association between sugar-sweetened and artificially sweetened soft drinks and type 2 diabetes: systematic review and dose–response meta-analysis of prospective studies. British Journal of Nutrition2014;112(5):725-34.">Greenwood 2014</a>). </p> </section> </section> <section id="CD012885-sec-0013"> <h3 class="title" id="CD012885-sec-0013">How the intervention might work</h3> <p>The mechanisms by which NNS might influence health outcomes in people with diabetes include improvement in glycaemic control and facilitation of weight management. </p> <p>One of the key elements in nutrition therapy for type 1 diabetes is carbohydrate‐counting meal planning and adjustments to insulin doses based on carbohydrate intake, in order to maintain blood glucose levels within the normal range. A simple diabetes meal planning approach such as portion control may be an appropriate nutrition strategy for individuals with type 2 diabetes. Use of NNS has the potential to reduce the overall caloric and carbohydrate intake if they substitute for caloric sweeteners, without compensation by intake of additional calories from other food sources (<a href="./references#CD012885-bbs2-0115" title="EvertAB , BoucherJL , CypressM , DunbarSA , FranzMJ , Mayer-DavisEJ , et al, American Diabetes Association. Nutrition therapy recommendations for the management of adults with diabetes. Diabetes Care2013;36(11):3821-42.">Evert 2013</a>). </p> <p>If people with diabetes use NNS to replace caloric sweeteners without caloric compensation, then NNS may also be useful in weight management. Since being overweight and obese can worsen glycaemic control and increase cardiometabolic risk, preventing weight gain in individuals with diabetes is considered to be important. Dietary changes can result in modest and sustained weight loss, and they may produce clinically meaningful reductions in glycosylated haemoglobin A1c (HbA1c) and triglycerides (<a href="./references#CD012885-bbs2-0096" title="American Diabetes Association. Obesity management for the treatment of type 2 diabetes. Diabetes Care2016;39(Suppl 1):S47–51.">ADA 2016</a>; <a href="./references#CD012885-bbs2-0149" title="PastorsJG , WarshawH , DalyA , FranzM , KulkarniK . The evidence for the effectiveness of medical nutrition therapy in diabetes management. Diabetes Care2002;25(3):608-13.">Pastors 2002</a>). </p> </section> <section id="CD012885-sec-0014"> <h3 class="title" id="CD012885-sec-0014">Why it is important to do this review</h3> <p>One systematic review focusing on the effects of FDA‐approved NNS in individuals with diabetes found that NNS do not appear to affect glycaemic control (<a href="./references#CD012885-bbs2-0158" title="Timpe BehnenEM , FergusonMC , CarlsonA . Do sugar substitutes have any impact on glycemic control in patients with diabetes?Journal of Pharmacy Technology2013;29:61-5.">Timpe Behnen 2013</a>). However, that systematic review was limited in that it included only studies published in English and only considered NNS available in the USA. New trials have been published since then that could provide additional relevant evidence. Furthermore, it is important to focus on determining the effects of regular NNS use on patient‐important outcomes, such as morbidity, mortality, and adverse effects, which <a href="./references#CD012885-bbs2-0158" title="Timpe BehnenEM , FergusonMC , CarlsonA . Do sugar substitutes have any impact on glycemic control in patients with diabetes?Journal of Pharmacy Technology2013;29:61-5.">Timpe Behnen 2013</a> did not address. </p> <p>Non‐nutritive sweeteners as part of nutrition therapy represent a simple and cheap intervention that might help decrease the need for antidiabetic drugs, insulin, or both, thereby delaying possible complications. Given that diabetes is a major public health problem worldwide, such an intervention might have huge benefits for health systems in terms of reducing burden and costs. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD012885-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD012885-sec-0015"></div> <p>To assess the effects of non‐nutritive sweeteners for diabetes mellitus.</p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD012885-sec-0016" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD012885-sec-0016"></div> <section id="CD012885-sec-0017"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD012885-sec-0018"> <h4 class="title">Types of studies</h4> <p>We included randomised controlled trials (RCTs).</p> </section> <section id="CD012885-sec-0019"> <h4 class="title">Types of participants</h4> <p>Individuals with type 1 or type 2 diabetes mellitus.</p> <section id="CD012885-sec-0020"> <h5 class="title">Diagnostic criteria for diabetes mellitus</h5> <p>In order to be consistent with changes in the classification and diagnostic criteria for diabetes mellitus over the years, the diagnosis should be established using the standard criteria valid at the time of trial commencement (e.g. <a href="./references#CD012885-bbs2-0094" title="Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care2003;26(Suppl 1):S5-20.">ADA 2003</a>; <a href="./references#CD012885-bbs2-0095" title="American Diabetes Association. Standards of medical care in diabetes - 2008. Diabetes Care2008;31(Suppl 1):S12-54. [PMID: 18165335]">ADA 2008</a>; <a href="./references#CD012885-bbs2-0161" title="AlbertiKM , ZimmetPZ . Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetic Medicine1998;15(7):539-53.">WHO 1998</a>). Trials should ideally describe diagnostic criteria. If necessary, we used the study authors' definition of diabetes mellitus. We planned to subject diagnostic criteria to a sensitivity analysis. </p> </section> </section> <section id="CD012885-sec-0021"> <h4 class="title">Types of interventions</h4> <p>We planned to investigate the following comparisons of intervention versus control/comparator.</p> <section id="CD012885-sec-0022"> <h5 class="title">Intervention</h5> <p> <ul id="CD012885-list-0001"> <li> <p>Any type of NNS, either alone or in combination with another NNS.</p> </li> <li> <p>NNS plus a behaviour‐changing intervention such as diet, exercise, or both.</p> </li> </ul> </p> </section> <section id="CD012885-sec-0023"> <h5 class="title">Comparisons</h5> <p> <ul id="CD012885-list-0002"> <li> <p>Usual diet versus NNS.</p> </li> <li> <p>No intervention versus NNS.</p> </li> <li> <p>Placebo versus NNS.</p> </li> <li> <p>Water versus NNS.</p> </li> <li> <p>NNS versus a different NNS.</p> </li> <li> <p>NNS versus NNS of a different dose.</p> </li> <li> <p>NNS versus a nutritive or low‐calorie sweetener.</p> </li> <li> <p>Behaviour‐changing intervention such as diet, exercise, or both versus NNS plus behaviour‐changing intervention. </p> </li> </ul> </p> <p>Concomitant interventions had to be similar in the intervention and comparator groups to allow fair comparisons and to isolate the effect of NNS on health outcomes. </p> </section> <section id="CD012885-sec-0024"> <h5 class="title">Minimum duration of intervention</h5> <p>We considered RCTs in which the intervention had a minimum duration of four weeks.</p> </section> <section id="CD012885-sec-0025"> <h5 class="title">Minimum duration of follow‐up</h5> <p>Minimum duration of follow‐up was four weeks after start of the intervention. We defined extended follow‐up periods (also called open‐label extension studies) as follow‐up of participants once the original trial as specified in the trial protocol had been terminated. </p> </section> <section id="CD012885-sec-0026"> <h5 class="title">Summary of specific exclusion criteria</h5> <p>None.</p> </section> </section> <section id="CD012885-sec-0027"> <h4 class="title">Types of outcome measures</h4> <p>We included outcomes that are measured for as long as follow‐up is carried out at any given time point. We classified the outcome measurement as medium and long term. We defined 'medium term' as at least four weeks to less than six months and 'long term' as six months or more. We used the data at the longest follow‐up available for the meta‐analyses. </p> <section id="CD012885-sec-0028"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD012885-list-0003"> <li> <p>HbA1c</p> </li> <li> <p>Body weight</p> </li> <li> <p>Adverse events</p> </li> </ul> </p> </section> <section id="CD012885-sec-0029"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD012885-list-0004"> <li> <p>Diabetes complications</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Anthropometric measures other than body weight</p> </li> <li> <p>Lipid profile</p> </li> <li> <p>Glucose levels (fasting and postprandial)</p> </li> <li> <p>Serum insulin</p> </li> <li> <p>Insulin sensitivity</p> </li> <li> <p>Socioeconomic effects</p> </li> </ul> </p> <p>We included trials reporting at least one of the listed primary or secondary outcome measures in the publication. Trials not reporting on any of our primary or secondary outcomes were excluded, but we reported some basic information for these trials in the 'Characteristics of studies awaiting classification' table. </p> </section> <section id="CD012885-sec-0030"> <h5 class="title">Method of outcome measurement</h5> <p> <ul id="CD012885-list-0005"> <li> <p>HbA1c: measured in % (mmol/mol).</p> </li> <li> <p>Body weight: measured in kilograms (kg).</p> </li> <li> <p>Adverse events: such as hypoglycaemic episodes, abdominal discomfort, flatulence, or diarrhoea measured at any time after participants had been randomised to intervention/comparator groups. </p> </li> <li> <p>Diabetes complications: defined as diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, and cardiovascular events. </p> </li> <li> <p>All‐cause mortality: defined as death from any cause and measured at any time after participants were randomised to intervention/comparator groups. </p> </li> <li> <p>Health‐related quality of life: evaluated by a validated instrument such as Audit of Diabetes‐Dependent Quality of Life (ADDQoL) or 36‐Item Short Form Health Survey (SF‐36). </p> </li> <li> <p>Anthropometric measures other than body weight (kg): defined as BMI (body mass index; kg/m²), waist circumference (cm), per cent of body fat (%), or waist‐to‐hip ratio. </p> </li> <li> <p>Lipid profile: analysed by total cholesterol, high‐density lipoprotein (HDL) cholesterol, low‐density lipoprotein (LDL) cholesterol, and triglycerides (TG). </p> </li> <li> <p>Glucose levels: fasting blood glucose levels (mg/dL) and postprandial blood glucose levels (mg/dL). </p> </li> <li> <p>Serum insulin: measured in microunits/mL.</p> </li> <li> <p>Insulin sensitivity: analysed by the homeostasis model assessment of insulin resistance (HOMA‐IR). </p> </li> <li> <p>Socioeconomic effects: such as direct costs defined as admission/readmission rates, average length of hospital stay, visits to general practitioner, visits to the emergency department; medication consumption; indirect costs defined as resources lost due to illness by the participant or their family member or absence from work. </p> </li> </ul> </p> </section> <section id="CD012885-sec-0031"> <h5 class="title">Timing of outcome measurement</h5> <p>With the exception of adverse events and all‐cause mortality (measured at any time after participants were randomised to intervention/comparator groups), we considered outcomes measured after a minimum follow‐up of four weeks. </p> </section> </section> </section> <section id="CD012885-sec-0032"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD012885-sec-0033"> <h4 class="title">Electronic searches</h4> <p>We searched the following sources from the inception of each database with no restrictions placed on the language of publication. </p> <p> <ul id="CD012885-list-0006"> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, <a href="http://crso.cochrane.org" target="_blank">crso.cochrane.org</a>) (searched on 23 May 2019). </p> </li> <li> <p>MEDLINE Ovid (Epub Ahead of Print, In‐Process &amp; Other Non‐Indexed Citations, Ovid MEDLINE (R) Daily and Ovid MEDLINE (R); from 1946 to 20 May 2019) (searched on 21 May 2019). </p> </li> <li> <p>Scopus (<a href="http://www.scopus.com" target="_blank">www.scopus.com</a>) (searched on 09 January 2019). </p> </li> <li> <p>US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (<a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a>) (searched on 23 May 2019). </p> </li> <li> <p>World Health Organization International Clinical Trials Registry Platform (WHO ICTRP, <a href="http://apps.who.int/trialsearch/" target="_blank">www.who.int/trialsearch</a>) (searched on 28 May 2019). </p> </li> </ul> </p> <p>We did not include Embase in our search as RCTs indexed in Embase are now prospectively added to CENTRAL via a highly sensitive screening process (<a href="./references#CD012885-bbs2-0107" title="Cochrane. CENTRAL creation details. www.cochranelibrary.com/central/central-creation (accessed 21 August 2018).">Cochrane 2018</a>). </p> <p>Details of the search strategies are shown in <a href="./appendices#CD012885-sec-0142">Appendix 1</a>. We applied no restrictions on the language of publication when searching the electronic databases or reviewing reference lists of identified trials. </p> </section> <section id="CD012885-sec-0034"> <h4 class="title">Searching other resources</h4> <p>We attempted to identify other potentially eligible trials or ancillary publications by searching the reference lists of included trials, (systematic) reviews, meta‐analyses, and health technology assessment reports. In addition, we contacted authors of included trials to identify any additional information on the retrieved trials and to determine if there were further trials that we may have missed. </p> <p>We did not use abstracts or conference proceedings for data extraction unless full data were available from the trial authors because this information source does not fulfil the CONSORT requirements, which consist of "an evidence‐based, minimum set of recommendations for reporting randomized trials" (<a href="./references#CD012885-bbs2-0108" title="SchulzKF , AltmanDG , MoherD , for the CONSORT Group. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomized Trials. Annals of Internal Medicine2010;152(11):726-32.">CONSORT 2010</a>; <a href="./references#CD012885-bbs2-0154" title="SchererRW , MeerpohlJJ , PfeiferN , SchmuckerC , SchwarzerG , vonElmE . Full publication of results initially presented in abstracts. Cochrane Database of Systematic Reviews2018, Issue 11. [DOI: 10.1002/14651858.MR000005.pub4]">Scherer 2018</a>). We planned to list key data of abstracts in an appendix. </p> <p>We defined grey literature as records detected in ClinicalTrials.gov or WHO ICTRP, and we additionally searched the database of the FDA (<a href="https://www.fda.gov/Food/" target="_blank">www.fda.gov/Food</a>). </p> </section> </section> <section id="CD012885-sec-0035"> <h3 class="title" id="CD012885-sec-0035">Data collection and analysis</h3> <section id="CD012885-sec-0036"> <h4 class="title">Selection of studies</h4> <p>Pairs of review authors (SL, IT, DK) independently screened the abstract, title, or both, of every record retrieved by the literature searches to determine which trials should be assessed further. We performed the screening using Covidence software (<a href="./references#CD012885-bbs2-0112" title="Veritas Health InnovationCovidence. Version accessed 19 October 2017. Melbourne, Australia: Veritas Health Innovation.Available at covidence.org.">Covidence</a>). We obtained the full texts of all potentially relevant records and screened these for eligibility. Any disagreements were resolved through consensus or by recourse to a third review author (SL, IT, DK, or JM). If we could not resolve a disagreement, we categorised the trial as a study awaiting classification and contacted the trial authors for clarification. We have presented a PRISMA flow diagram to describe the process of trial selection (<a href="./references#CD012885-bbs2-0140" title="LiberatiA , AltmanDG , TetzlaffJ , MulrowC , GøtzschePC , IoannidisJPA , et al. The PRISMA statement for reporting systematic and meta-analyses of studies that evaluate interventions: explanation and elaboration. PLOS Medicine2009;6(7):1-28.">Liberati 2009</a>). All articles excluded after full‐text assessment and the reasons for their exclusion are described in <a href="./references#CD012885-sec-0171" title="">Characteristics of excluded studies</a> tables. </p> </section> <section id="CD012885-sec-0037"> <h4 class="title">Data extraction and management</h4> <p>Pairs of review authors (SL, IT, DK) independently extracted key participant and intervention characteristics of the trials that met our inclusion criteria. We described interventions using the 'template for intervention description and replication' (TIDieR) checklist (<a href="./references#CD012885-bbs2-0130" title="HoffmannTC , GlasziouPP , BoutronI , MilneR , PereraR , MoherD , et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ2014;348:g1687.">Hoffmann 2014</a>; <a href="./references#CD012885-bbs2-0131" title="HoffmannTC , OxmanAD , IoannidisJP , MoherD , LassersonTJ , ToveyDI , et al. Enhancing the usability of systematic reviews by improving the consideration and description of interventions. BMJ2017;358:j2998.">Hoffmann 2017</a>). </p> <p>We recorded data on efficacy outcomes and adverse events using standardised data extraction sheets from the Cochrane Metabolic and Endocrine Disorders Group. Any disagreements were resolved by discussion or by consultation with a third review author (SL, IT, DK, or JM) if required. For details see <a href="./references#CD012885-sec-0170" title="">Characteristics of included studies</a>; <a href="#CD012885-tbl-0003">Table 2</a>; <a href="./appendices#CD012885-sec-0143">Appendix 2</a>; <a href="./appendices#CD012885-sec-0144">Appendix 3</a>; <a href="./appendices#CD012885-sec-0145">Appendix 4</a>; <a href="./appendices#CD012885-sec-0146">Appendix 5</a>; <a href="./appendices#CD012885-sec-0147">Appendix 6</a>; <a href="./appendices#CD012885-sec-0148">Appendix 7</a>; <a href="./appendices#CD012885-sec-0149">Appendix 8</a>; <a href="./appendices#CD012885-sec-0150">Appendix 9</a>; <a href="./appendices#CD012885-sec-0151">Appendix 10</a>; <a href="./appendices#CD012885-sec-0152">Appendix 11</a>; <a href="./appendices#CD012885-sec-0153">Appendix 12</a>; <a href="./appendices#CD012885-sec-0154">Appendix 13</a>; <a href="./appendices#CD012885-sec-0155">Appendix 14</a>; <a href="./appendices#CD012885-sec-0156">Appendix 15</a>; <a href="./appendices#CD012885-sec-0157">Appendix 16</a>; <a href="./appendices#CD012885-sec-0158">Appendix 17</a>; <a href="./appendices#CD012885-sec-0159">Appendix 18</a>; <a href="./appendices#CD012885-sec-0160">Appendix 19</a>. </p> <div class="table" id="CD012885-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID (trial design)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed (primary outcome) (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: Splenda 1.5 g 3 times a day, dissolved in 125 to 250 mL water</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: D‐tagatose 15 g 3 times a day, dissolved in 125 to 250 mL water</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" class="headercell" colspan="3" rowspan="1" valign="top"></td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>494</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>356</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>204</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>41.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: steviol glycoside capsules 250 mg 3 times a day (92% purity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Power analysis were also conducted to determine whether the samples were large enough to allow for the detection of a clinically significant change between baseline and post treatment levels within the control and treatment groups. A clinically significant difference was defined based on the range of 'normal' values for each of the parameters considered." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 + 15<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo capsules 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 + 15<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>53</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>46</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>46</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.8</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: rebaudioside A 250 mg 4 times a day in capsules (97% purity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The study was designed to provide 90% power (α = 0.05, two‐sided) to detect a 0.5% difference in HbA1c response between treatment groups, assuming a standard deviation of 0.8%." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo capsules 4 times a day (microcrystalline cellulose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>122</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>122</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>116</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sucralose 667 mg daily in capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The number of subjects was based on achieving at least 90% power to detect a 0.6 treatment group difference in percent HbA1c change from baseline. Post‐study analysis showed that the study provided more than 99.99% power to detect this difference, and more than 90% to detect a difference of 0.3." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>17 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo (cellulose) capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>136</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>133<sup>c</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>128</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>94.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: aspartame 162 mg daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: sucrose 45 g daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: saccharin and starch 30 g daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: sucrose 28 g daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sodium‐cyclamate, ad libitum (348 ± 270 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: sucrose, ad libitum (24 ± 13 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: aspartame 2.7 g daily, in capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>18 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo (cornstarch) 1.8 g daily in capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>63</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>98.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: aspartame 300 mg capsules, 2 capsules 3 times daily added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>13 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: matched placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>75</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>‐</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>69</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>92</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Grand total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>437</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>364</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>432</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>333</b><sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>979</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>661</b><sup>e</sup> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>‐: denotes not reported</p> <p><b>C</b> : comparator; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>I</b> : intervention; <b>RCT</b>: randomised controlled trial. </p> <p><sup>a</sup>We provided numbers for the intention‐to‐treat analysis. Authors also performed a per‐protocol analysis, with 119 participants in the Splenda and 85 in the tagatose group.<br/><sup>b</sup>This trial included participants with type 1 and type 2 diabetes and participants without diabetes. We only reported on participants with type 1 and type 2 diabetes.<br/><sup>c</sup>For the two primary outcomes of the trial, the number of participants included in the analyses was reported only for fasting plasma glucose, but not for HbA1c values.<br/><sup>d</sup>Not all trials described the number of participants randomised to each intervention/comparator group, therefore the numbers do not add up correctly.<br/><sup>e</sup>There are cross‐over trials amongst the included trials, therefore the numbers do not add up correctly. </p> </div> </div> <p>We attempted to find the protocol for each included trial and reported primary, secondary, and other outcomes in comparison with data in publications in <a href="./appendices#CD012885-sec-0150">Appendix 9</a> to assess risk of selective outcome reporting. </p> <p>We emailed all authors of included trials to enquire as to whether they would be willing to answer questions regarding their trials. The results of this survey are presented in <a href="./appendices#CD012885-sec-0157">Appendix 16</a>. We thereafter sought relevant missing information on the trial from the primary trial author(s), if required. </p> <section id="CD012885-sec-0038"> <h5 class="title">Dealing with duplicate and companion publications</h5> <p>In the event of duplicate publications, companion documents, or multiple reports of a primary trial, we maximised the information yield by collating all available data, and used the most complete data set aggregated across all known publications. We listed duplicate publications, companion documents, multiple reports of a primary trial, and trial documents of included trials (such as trial registry information) as secondary references under the study ID of the included trial. Furthermore, we also listed duplicate publications, companion documents, multiple reports of a trial, and trial documents of excluded trials (such as trial registry information) as secondary references under the study ID of the excluded trial. </p> </section> <section id="CD012885-sec-0039"> <h5 class="title">Data from clinical trial registries</h5> <p>If data from included trials were available as study results in clinical trial registries such as ClinicalTrials.gov or similar sources, we made full use of this information and extracted the data. If there was also a full publication of the trial, we collated and critically appraised all available data. If an included trial was marked as a completed study in a clinical trial registry but no additional information (study results, publication, or both) was available, we added this trial to the 'Characteristics of studies awaiting classification' table. </p> </section> </section> <section id="CD012885-sec-0040"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Pairs of review authors (SL, IT, DK) independently assessed the risk of bias of each included trial. Any disagreements were resolved by consensus or by consultation with a third review author (SL, IT, DK, or JM). In case of disagreement, we consulted the rest of the author team and made a judgement based on consensus. If adequate information was not available from publications, trial protocols, or other sources, we contacted the trial authors to request missing data on the 'Risk of bias' domains. </p> <p>We used the Cochrane 'Risk of bias' assessment tool (<a href="./references#CD012885-bbs2-0129" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019b</a>), to assign assessments of low, high, or unclear risk of bias (for details see <a href="./appendices#CD012885-sec-0143">Appendix 2</a>; <a href="./appendices#CD012885-sec-0144">Appendix 3</a>). We evaluated individual bias items as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, according to the criteria and associated categorisations therein (<a href="./references#CD012885-bbs2-0129" title="HigginsJP , SavovićJ , PageMJ , ElbersRG , SterneJA . Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019b</a>). </p> <section id="CD012885-sec-0041"> <h5 class="title">Summary assessment of risk of bias</h5> <p>A 'Risk of bias' graph and 'Risk of bias' summary figure are shown in Figure 2 and Figure 3. </p> <p>We distinguished between self‐reported and investigator‐assessed outcome measures.</p> <p>We considered the following self‐reported outcomes.</p> <p> <ul id="CD012885-list-0007"> <li> <p>Body weight</p> </li> <li> <p>Adverse events</p> </li> <li> <p>Health‐related quality of life</p> </li> <li> <p>Glucose levels</p> </li> </ul> </p> <p>We considered the following investigator‐assessed outcomes.</p> <p> <ul id="CD012885-list-0008"> <li> <p>HbA1c</p> </li> <li> <p>Body weight</p> </li> <li> <p>Diabetes complications</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Anthropometric measures other than body weight</p> </li> <li> <p>Lipid profile</p> </li> <li> <p>Glucose levels</p> </li> <li> <p>Serum insulin</p> </li> <li> <p>Insulin sensitivity</p> </li> <li> <p>Socioeconomic effects</p> </li> </ul> </p> <section id="CD012885-sec-0042"> <h6 class="title">Risk of bias for a trial across outcomes</h6> <p>Some 'Risk of bias' domains, such as selection bias (sequence generation and allocation sequence concealment), affect the risk of bias across all outcome measures in a trial. In case of high risk of selection bias, we marked all outcomes investigated in the associated trial as at high risk of bias. Otherwise, we did not perform a summary assessment of the risk of bias across all outcomes for a trial. </p> </section> <section id="CD012885-sec-0043"> <h6 class="title">Risk of bias for an outcome within a trial and across domains</h6> <p>We assessed the risk of bias for an outcome measure by including all entries relevant to that outcome (i.e. both trial‐level entries and outcome‐specific entries). We considered low risk of bias to denote a low risk of bias for all key domains; unclear risk to denote an unclear risk of bias for one or more key domains; and high risk to denote a high risk of bias for one or more key domains. </p> </section> <section id="CD012885-sec-0044"> <h6 class="title">Risk of bias for an outcome across trials and across domains</h6> <p>These are the main summary assessments that we incorporated into our judgements regarding the certainty of evidence in the 'Summary of findings' tables. We defined outcomes as being at low risk of bias when most information came from trials at low risk of bias; unclear risk when most information came from trials at low or unclear risk of bias; and high risk when a sufficient proportion of information came from trials at high risk of bias. </p> </section> </section> </section> <section id="CD012885-sec-0045"> <h4 class="title">Measures of treatment effect</h4> <p>When at least two included trials were available for a comparison of a given outcome, we tried to express dichotomous data as a risk ratio (RR) or an odds ratio (OR), with 95% confidence intervals (CIs). For continuous outcomes measured on the same scale (e.g. weight loss in kg), we estimated the intervention effect using the mean difference (MD) with 95% CIs. For continuous outcomes measuring the same underlying concept (e.g. health‐related quality of life) but using different measurement scales, we planned to calculate the standardised mean difference (SMD) with 95% CIs. </p> </section> <section id="CD012885-sec-0046"> <h4 class="title">Unit of analysis issues</h4> <p>We took into account the level at which randomisation occurred, such as cross‐over trials, and multiple observations for the same outcome. For more than one available comparison from the same trial eligible for inclusion in the same meta‐analysis, we planned to either combine groups to create a single pair‐wise comparison or appropriately reduce the sample size so that the same participants did not contribute data to the meta‐analysis more than once (splitting the 'shared' group into two or more groups). Whilst the latter approach offers some solution to adjusting the precision of the comparison, it does not account for correlation arising from the same set of participants being in multiple comparisons (Higgins 2019a). </p> <p>We attempted to re‐analyse cluster‐RCTs that did not appropriately adjust for potential clustering of participants within clusters in their analyses and therefore the variance of the intervention effects was inflated by a design effect. Calculation of a design effect involves estimation of an intracluster correlation coefficient (ICC). We planned to obtain estimates of ICCs through contact with authors or impute them, either using estimates from other included trials that reported ICCs or using external estimates from empirical research (e.g. <a href="./references#CD012885-bbs2-0101" title="BellML , McKenzieJE . Designing psycho-oncology randomised trials and cluster randomised trials: variance components and intra-cluster correlation of commonly used psychosocial measures. Psycho-Oncology2013;22:1738-47.">Bell 2013</a>). We planned to examine the impact of clustering using sensitivity analyses. </p> </section> <section id="CD012885-sec-0047"> <h4 class="title">Dealing with missing data</h4> <p>If possible, we obtained missing data from the authors of the included trials. We carefully evaluated important numerical data such as screened, randomly assigned participants as well as intention‐to‐treat, as‐treated, and per‐protocol populations. We investigated attrition rates (e.g. dropouts, losses to follow‐up and withdrawals), and critically appraised issues concerning missing data and use of imputation methods (e.g. last observation carried forward) if individuals were missing from the reported results. </p> <p>When change from baseline is the outcome of interest, missing standard deviations (SD) for changes from baseline constitute a special case. If the trial authors did not explicitly present these data, and we could not obtain them from the authors, we calculated the mean change in each group by subtracting the final mean from the baseline mean. When baseline and final SDs were available, we imputed the missing SD using an imputed value for the correlation coefficient (<a href="./references#CD012885-bbs2-0093" title="AbramsKR , GilliesCL , LambertPC . Meta-analysis of heterogeneously reported trials assessing change from baseline. Statistics in Medicine2005;24:3823-44.">Abrams 2005</a>; <a href="./references#CD012885-bbs2-0120" title="FollmannD , ElliottP , SuhI , CutlerJ . Variance imputation for overviews of clinical trials with continuous response. Journal of Clinical Epidemiology1992;45:769-73.">Follmann 1992</a>). Here, we planned to use a correlation coefficient of zero (<a href="./references#CD012885-bbs2-0128" title="HigginsJP , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019a</a>, see 16.1.3.2 'Imputing standard deviations for changes from baseline'), and wanted to check in sensitivity analyses whether the overall result of the analysis was robust to the use of different correlation coefficients. We planned to report per outcome which trials with imputed SDs were included. For cross‐over trials with mean difference as the measure of treatment effect, missing SD of the difference was imputed based on correlation coefficient obtained from trials where SD of the difference was given. If there was no such trial, we used the value of 0.5, performing sensitivity analyses for 0 and 0.8 (<a href="./references#CD012885-bbs2-0128" title="HigginsJP , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019a</a>, see 16.4.6.1 'Mean differences'). </p> </section> <section id="CD012885-sec-0048"> <h4 class="title">Assessment of heterogeneity</h4> <p>In the event of substantial clinical or methodological heterogeneity, we did not report trial results as the pooled effect estimate in a meta‐analysis. </p> <p>We identified heterogeneity (inconsistency) by visually inspecting the forest plots and by using a standard Chi² test with a significance level of α = 0.1 (<a href="./references#CD012885-bbs2-0113" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). In view of the low power of this test, we also considered the I² statistic — which quantifies inconsistency across trials —to assess the impact of heterogeneity on the meta‐analysis (<a href="./references#CD012885-bbs2-0125" title="HigginsJT , ThompsonSG . Quantifying heterogeneity in a meta-analysis. Statistics in Medicine2002;21:1539-58.">Higgins 2002</a>; <a href="./references#CD012885-bbs2-0126" title="HigginsJT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta-analysis. BMJ2003;327(7414):557-60.">Higgins 2003</a>). When we found heterogeneity, we attempted to determine the possible reasons for it by examining individual characteristics of the trial and subgroups. </p> </section> <section id="CD012885-sec-0049"> <h4 class="title">Assessment of reporting biases</h4> <p>If we included 10 or more trials that investigated a given outcome, we would use funnel plots to assess small‐trial effects. There are several possible explanations for funnel plot asymmetry, including true heterogeneity of effect with respect to trial size, poor methodological design (and hence small‐trial bias), and publication bias (<a href="./references#CD012885-bbs2-0157" title="SterneJA , EggerM , MoherD , BoutronI , editor(s). Chapter 10: Addressing reporting biases. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017. Available from www.training.cochrane.org/handbook.">Sterne 2017</a>). We therefore planned to interpret the results carefully (<a href="./references#CD012885-bbs2-0156" title="SterneJA , SuttonAJ , IoannidisJP , TerrinN , JonesDR , LauJ , et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ2011;343:d4002.">Sterne 2011</a>). </p> </section> <section id="CD012885-sec-0050"> <h4 class="title">Data synthesis</h4> <p>We planned to undertake (or display) a meta‐analysis only if we judged the participants, interventions, comparisons, and outcomes to be sufficiently similar to ensure a result that was clinically meaningful. Unless good evidence showed homogeneous effects across trials of different methodological quality, we primarily summarised data that are of low risk of bias using a random‐effects model (<a href="./references#CD012885-bbs2-0163" title="WoodL , EggerM , GluudLL , SchulzKF , JüniP , AltmanDG , et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ2008;336(7644):601-5.">Wood 2008</a>). We interpreted random‐effects meta‐analyses with due consideration to the whole distribution of effects and planned to present prediction intervals (<a href="./references#CD012885-bbs2-0102" title="BorensteinM , HigginsJP , HedgesLV , RothsteinHR . Basics of meta-analysis: I² is not an absolute measure of heterogeneity. Research Synthesis Methods2017;8(1):5-18.">Borenstein 2017a</a>; <a href="./references#CD012885-bbs2-0103" title="BorensteinM . Prediction intervals. www.meta-analysis.com/prediction (accessed 3 July 2017).">Borenstein 2017b</a>; <a href="./references#CD012885-bbs2-0127" title="HigginsJPT , ThompsonSG , SpiegelhalterDJ . A re-evaluation of random-effects meta-analysis. Journal of the Royal Statistical Society: Series A (Statistics in Society)2009;172(1):137-59.">Higgins 2009</a>). A prediction interval needs at least three trials to be calculated and specifies a predicted range for the true treatment effect in an individual trial (<a href="./references#CD012885-bbs2-0152" title="RileyRD , HigginsJP , DeeksJJ . Interpretation of random effects meta-analyses. BMJ2011;342:d549.">Riley 2011</a>). For rare events such as event rates below 1%, we used Peto's odds ratio method, provided that there was no substantial imbalance between intervention and comparator group sizes, and intervention effects were not exceptionally large. In addition, we performed statistical analyses according to the statistical guidelines presented in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012885-bbs2-0113" title="DeeksJJ , HigginsJP , Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Deeks 2019</a>). </p> </section> <section id="CD012885-sec-0051"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We expected the following characteristics to introduce clinical heterogeneity, and we planned to carry out subgroup analyses for these, including investigation of interactions (<a href="./references#CD012885-bbs2-0098" title="AltmanDG , BlandJM . Interaction revisited: the difference between two estimates. BMJ2003;326(7382):219. [PMID: 12543843]">Altman 2003</a>). </p> <p> <ul id="CD012885-list-0009"> <li> <p>Type 1 or type 2 diabetes.</p> </li> <li> <p>Age groups (children: 0 to 18 years; adults: 19 to 64 years; elderly: 65 years or older). </p> </li> <li> <p>Length of non‐nutritive sweetener intervention (medium versus long term).</p> </li> <li> <p>Different types of non‐nutritive sweeteners used.</p> </li> <li> <p>Different types of sources of non‐nutritive sweeteners (liquid, mixed, solid).</p> </li> </ul> </p> </section> <section id="CD012885-sec-0052"> <h4 class="title">Sensitivity analysis</h4> <p>We planned to perform sensitivity analyses to explore the influence of the following factors (when applicable) on effect sizes by restricting analysis to the following. </p> <p> <ul id="CD012885-list-0010"> <li> <p>Published trials.</p> </li> <li> <p>Effect of risk of bias, as specified in the <a href="#CD012885-sec-0040">Assessment of risk of bias in included studies</a> section. </p> </li> <li> <p>Very long or large trials to establish the extent to which they dominated the results.</p> </li> </ul> </p> <p>We used of the following filters, if applicable: diagnostic criteria, imputation used, language of publication (English versus other languages), source of funding (industry versus other), or country (depending on data). </p> <p>We also tested the robustness of results by repeating the analyses using different statistical models (fixed‐effect and random‐effects models). </p> </section> <section id="CD012885-sec-0053"> <h4 class="title">Certainty of the evidence</h4> <p>We presented the overall certainty of the evidence for each outcome specified below, according to the GRADE approach, which takes into account issues related to internal validity (risk of bias, inconsistency, imprecision, publication bias) and external validity (such as directness of results)<i>.</i> Two review authors (SL, DK) independently rated the certainty of the evidence for each outcome. We resolved any differences in assessment by discussion or by consultation with a third review author (SL, IT, DK, JM). </p> <p>We included 'Checklists to aid consistency and reproducibility of GRADE assessments' (<a href="./appendices#CD012885-sec-0158">Appendix 17</a>; <a href="./appendices#CD012885-sec-0159">Appendix 18</a>; <a href="./appendices#CD012885-sec-0160">Appendix 19</a>) to help with standardisation of the 'Summary of findings' tables (<a href="./references#CD012885-bbs2-0144" title="MeaderN , KingK , LlewellynA , NormanG , BrownJ , RodgersM , et al. A checklist designed to aid consistency and reproducibility of GRADE assessments: development and pilot validation. Systematic Reviews2014;3:82.">Meader 2014</a>). We presented results for the outcomes as described in the Types of outcome measures section. If meta‐analysis was not possible, we presented the results in a narrative format in the 'Summary of findings' table. We justified all decisions to downgrade the certainty of the evidence using footnotes, and made comments to aid the reader's understanding where necessary. </p> <section id="CD012885-sec-0054"> <h5 class="title">'Summary of findings' table</h5> <p>We presented a summary of the evidence in a 'Summary of findings' table. This provides key information about the best estimate of the magnitude of the effect, in relative terms and as absolute differences, for each relevant comparison of alternative management strategies; the numbers of participants and trials addressing each important outcome; and a rating of overall confidence in effect estimates for each outcome. We created the 'Summary of findings' table based on the methods described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD012885-bbs2-0155" title="SchünemannHJ , HigginsJP , VistGE , GlasziouP , AklEA , SkoetzN , et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the confidence in or quality of the evidence. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors), Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Schünemann 2019</a>), using the Review Manager 5 table editor (<a href="./references#CD012885-bbs2-0151" title="The Nordic Cochrane Centre, The Cochrane CollaborationReview Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Interventions presented in the 'Summary of findings' table were any type of NNS with or without a behaviour‐changing intervention, and comparators were usual diet, no intervention, placebo, water, or a behaviour‐changing intervention alone. </p> <p>We reported the following outcomes, listed according to priority.</p> <p> <ol id="CD012885-list-0011"> <li> <p>Health‐related quality of life</p> </li> <li> <p>Diabetes complications</p> </li> <li> <p>All‐cause mortality</p> </li> <li> <p>Adverse events</p> </li> <li> <p>HbA1c</p> </li> <li> <p>Body weight (kg)</p> </li> <li> <p>Socioeconomic effects</p> </li> </ol> </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD012885-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD012885-sec-0055"></div> <section id="CD012885-sec-0056"> <h3 class="title">Description of studies</h3> <p>For a detailed description of trials, see <a href="#CD012885-tbl-0003">Table 2</a>, <a href="./references#CD012885-sec-0170" title="">Characteristics of included studies</a> and <a href="./references#CD012885-sec-0171" title="">Characteristics of excluded studies</a>. </p> <section id="CD012885-sec-0057"> <h4 class="title">Results of the search</h4> <p>The search was first run in January 2018, and then updated in May 2019 (see <a href="./appendices#CD012885-sec-0142">Appendix 1</a> for details on search strategies). We retrieved 1699 unique records. Most of the references clearly did not meet the inclusion criteria based on title and abstract review and were excluded (<a href="#CD012885-fig-0001">Figure 1</a>). We evaluated 94 full texts or records to determine their eligibility for inclusion in the review. Nine RCTs published in 11 records met our inclusion criteria. </p> <div class="figure" id="CD012885-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Trial flow diagram." data-id="CD012885-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> </div> <section id="CD012885-sec-0058"> <h5 class="title">Ongoing trials</h5> <p>We did not identify ongoing trials matching our in‐ and exclusion criteria.</p> </section> </section> <section id="CD012885-sec-0059"> <h4 class="title">Included studies</h4> <p>A detailed description of the characteristics of included trials is presented in <a href="./references#CD012885-sec-0170" title="">Characteristics of included studies</a>; <a href="#CD012885-tbl-0003">Table 2</a>; <a href="./appendices#CD012885-sec-0145">Appendix 4</a>; <a href="./appendices#CD012885-sec-0146">Appendix 5</a>; <a href="./appendices#CD012885-sec-0147">Appendix 6</a>; <a href="./appendices#CD012885-sec-0148">Appendix 7</a>; <a href="./appendices#CD012885-sec-0149">Appendix 8</a>; <a href="./appendices#CD012885-sec-0150">Appendix 9</a>; <a href="./appendices#CD012885-sec-0151">Appendix 10</a>; <a href="./appendices#CD012885-sec-0152">Appendix 11</a>; <a href="./appendices#CD012885-sec-0153">Appendix 12</a>; <a href="./appendices#CD012885-sec-0154">Appendix 13</a>; <a href="./appendices#CD012885-sec-0155">Appendix 14</a>; <a href="./appendices#CD012885-sec-0156">Appendix 15</a>; <a href="./appendices#CD012885-sec-0157">Appendix 16</a>. The following is an overview of the main results. </p> <section id="CD012885-sec-0060"> <h5 class="title">Source of data</h5> <p>All included trials were published as full publications, and no additional information was found in trial registries or other trial documents (see <a href="./appendices#CD012885-sec-0150">Appendix 9</a>). We contacted authors of all included trials by email (<a href="./appendices#CD012885-sec-0157">Appendix 16</a>). We also contacted the trial authors when important information was needed to make a final decision on the inclusion or exclusion of a study (<a href="./appendices#CD012885-sec-0157">Appendix 16</a>). </p> <p>One trial identified in a trial registry was finally excluded based on information received from the authors via email (<a href="./references#CD012885-bbs2-0022" title="EUCTR2006-002395-18-DK. Intervention studier med steviol til belysning af dosis respons forhold samt langtidseffekt hos personer med type 2 diabetes. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002395-18/DK (accessed 3 August 2018). ">EUCTR2006‐002395‐18‐DK</a>). In the case of other trial methodological issues that could be resolved through email correspondence with the authors, we used this information to assess the risk of bias (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). </p> </section> <section id="CD012885-sec-0061"> <h5 class="title">Comparisons</h5> <p>In five trials NNS were compared to placebo (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), whilst in three trials NNS supplementation was compared to a supplement containing sucrose (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>). One trial compared NNS to another type of sweetener (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). </p> <p>The type of NNS varied widely amongst trials: in two trials a <i>Stevia rebaudiana</i>‐based product was compared to placebo (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>); in one trial sucralose was compared to placebo (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>); and in two trials aspartame was compared to placebo (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). In the trials using a sucrose‐containing comparator, the investigated NNS were: aspartame (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>), saccharin (<a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>), or cyclamate (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). In one trial a <i>Stevia rebaudiana</i>‐based product was compared to tagatose (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). </p> </section> <section id="CD012885-sec-0062"> <h5 class="title">Overview of trial populations</h5> <p>The number of participants initially screened was described in three trials, ranging from 10, in <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, to 175, in <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>. </p> <p>A total of 661 of 979 randomised participants completed the trials, of these 364 were randomised to the intervention and 333 to the comparator group (see <a href="#CD012885-tbl-0003">Table 2</a>). The proportion of randomised participants completing the trial ranged between 41.3%, in <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>, and 100%, in <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>. Individual final sample size ranged from 9, in <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>, to 204, in <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>. </p> </section> <section id="CD012885-sec-0063"> <h5 class="title">Trial design</h5> <p>Trials were published between the years 1976, <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>, and 2015, <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>. Dates when trials were performed were not clearly stated in trials. </p> <p>Six trials were parallel RCTs (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), whilst three trials had a cross‐over design (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>). Five trials with parallel design had placebo as the comparator (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), and one used another type of sweetener as comparator (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). The three cross‐over trials compared NNS to sucrose. </p> <p>Seven trials performed blinding of participants and personnel (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>); one trial clearly stated that participants were not blinded (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>); and the remaining trial reported no information on blinding (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). Blinding of outcome assessors was generally not reported. </p> <p>Six trials had a run‐in period with a duration of either one week (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), two weeks (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>), four weeks (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>), or eight weeks (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). In one of these studies participants received placebo capsules two times a day during the run‐in period (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>). The duration of the intervention in the included trials varied from four weeks, in <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, to 10 months, in <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>. Only one trial followed participants after the intervention period (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>). </p> <p>The number of randomised participants varied from nine in a small cross‐over trial, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>, to 494 in a parallel trial, <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>. Four trials were multicentre trials (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), whilst the others were conducted in only one centre. </p> <p>None of the trials was terminated prematurely.</p> </section> <section id="CD012885-sec-0064"> <h5 class="title">Settings</h5> <p>All trials were performed in outpatient settings.</p> </section> <section id="CD012885-sec-0065"> <h5 class="title">Participants</h5> <p>One trial included only individuals with type 1 diabetes (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>); two trials included both individuals with type 1 and 2 diabetes (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>), whilst all other trials included participants with type 2 diabetes only. Duration of diabetes was reported in two trials for type 1, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, and in four trials for type 2 diabetes (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>); duration of disease was more than one year, <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, or more than five years, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>, for individuals with type 1 diabetes, whilst it ranged from more than one year, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>, to a mean duration of 10.2 years, <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>, in those with type 2 diabetes. </p> <p>All trials included adult males and females. Mean age of participants at baseline was reported in six trials (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>, <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>), ranging from 25.4 to 65.6 years. Two studies provided age range of participants (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). </p> <p>Ethnicity was reported in three trials (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>): two trials included mainly white people, while the third trial included mainly Asian participants (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). Six of the nine included trials were conducted partly, <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>, or fully in the USA (<a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). None of the included trials involved participants from low‐income countries. </p> <p>Seven trials reported baseline HbA1c levels. Three trials included individuals with HbA1c ≤ 7.5% at screening (type 2 diabetes group in <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). One trial included individuals with a mean baseline HbA1c &gt; 9.5% (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>), whilst three trials included participants with a mean baseline HbA1c between 7.7% and 9.5% (type 1 diabetes group in <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>). </p> <p>Six trials reported BMI at baseline. Individuals with type 1 diabetes in two studies, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, and individuals with type 2 diabetes in one study, <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>, had a normal BMI, whilst other trials including those with type 2 diabetes reported a baseline mean BMI of either 25 kg/m² to 30 kg/m², <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>, or 30 kg/m² to 35 kg/m², <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>. </p> <p>In two trials participants were reported to have comorbidities: hypertension, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>, or dyslipidaemia, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>, both of which were treated with medication. </p> <p>Major exclusion criteria, mentioned in at least two trials, were comorbidities such as cardiovascular diseases (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>), renal failure (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>), or poorly controlled hypertension (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>); acute illness (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>); or pregnancy (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). In five trials no exclusion criteria were mentioned (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). </p> </section> <section id="CD012885-sec-0066"> <h5 class="title">Diagnosis</h5> <p>Only three publications described how diabetes was diagnosed in the trial. In one trial diabetes diagnosis was defined based on the classification of an international workgroup sponsored by the National Diabetes Data Group of the US National Institutes of Health (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>), whilst in another trial diabetes was established by a fasting plasma glucose &gt; 140 mg/dL, an abnormal oral glucose tolerance test as interpreted by the US Public Health Service criteria, or an unequivocal history of diabetes (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). In the third trial diagnosis of diabetes was established "according to WHO criteria" (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). </p> </section> <section id="CD012885-sec-0067"> <h5 class="title">Interventions</h5> <p>In five of the nine trials NNS were provided in capsule form (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). In two trials NNS were added to the usual diet (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>), whilst in one trial participants were instructed to consume either NNS or sucrose ad libitum, and the consumed amounts were measured (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). </p> <p>Aspartame was administered in three trials (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), in a daily dose ranging from 162 mg, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>, to 2.7 g, <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>. Cyclamate was consumed by participants one trial, ad libitum with a mean daily dose of 348 mg (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). Saccharin was consumed in one trial, in combination with starch, at 30 g daily (<a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>). <i>Stevia rebaudiana</i>‐based products were consumed in two trials, in the form of 250 mg capsules, administered three times a day, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>, or four times a day, <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>. Sucralose was the dietary supplement used in two trials, administered in the form of 667 mg capsules, <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>, or 1500 mg dissolved in water, <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>. </p> </section> <section id="CD012885-sec-0068"> <h5 class="title">Outcomes</h5> <p>Three trials specified primary outcomes (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>), one of them in the full text of the publication, but not in the abstract (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>), whilst another trial specified the primary outcome only in the abstract of the publication (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>). In the third trial the primary outcome was specified in two trial registries, the publication abstract, and the main text of the publication with some discrepancies between information in the registries and the full‐text publication (adverse events were listed amongst primary outcomes in the publication, but not in the registry entries) (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). Secondary outcomes were explicitly stated in one trial (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). For full details see <a href="./appendices#CD012885-sec-0150">Appendix 9</a>. </p> <p>All included trials reported at least one of the primary outcomes of relevance for this review. Eight trials assessed HbA1c (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). Seven trials assessed body weight (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). One trial did not report data on body weight (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>), whilst another trial reported body weight data as change from baseline to the average of values at weeks 12 and 16 (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). </p> <p>Adverse events were assessed in six trials (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). In two of these trials adverse events were not specified; the authors only stated that "there were no significant differences between the treatment groups in the type, number, or severity of adverse events reported" (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>), or that "subjects exhibited no symptoms that could be attributed to the administration" of the NNS or placebo (<a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). Four trials reported data on adverse events (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). </p> <p>None of the included trials investigated all‐cause mortality, diabetes complications, health‐related quality of life, or socioeconomic effects. </p> </section> </section> <section id="CD012885-sec-0069"> <h4 class="title">Excluded studies</h4> <p>We excluded 83 articles or records after full‐text screening (<a href="#CD012885-fig-0001">Figure 1</a>). Excluded references are listed in <a href="./references#CD012885-sec-0171" title="">Characteristics of excluded studies</a>. </p> <p>We excluded 27 records because they did not describe a primary study (<a href="./references#CD012885-bbs2-0011" title="No authors listed. Saccharin substitutes for diabetics. Geriatrics1979;34(10):15. ">Anonymous 1979</a>; <a href="./references#CD012885-bbs2-0012" title="Barbosa-MartínE , Sabido-CortésD , Aranda-GozálezI , Betancur-AnconaD . Use of stevia rebaudiana extract as a sweetener of chocolates for people with diabetes. In: Stevia rebaudiana: Chemical Composition, Uses and Health Promoting Aspects. Nova Science Publishers, 2014:147-58. ">Barbosa Martín 2014</a>; <a href="./references#CD012885-bbs2-0013" title="BastakiS . Pharmacotherapy of nonnutritive sweeteners in diabetes mellitus. International Journal of Diabetes and Metabolism2015;23(1):11-2. ">Bastaki 2015</a>; <a href="./references#CD012885-bbs2-0015" title="BeringerA . Are sweetening substances dangerous for diabetics?Wiener Medizinische Wochenschrift1973;123(4):41-8. ">Beringer 1973</a>; <a href="./references#CD012885-bbs2-0017" title="BloomgardenZT . Nonnutritive sweeteners, fructose, and other aspects of diet. Diabetes Care2011;34(8):1887. ">Bloomgarden 2011</a>; <a href="./references#CD012885-bbs2-0018" title="ChantelauE . Sugar substitutes in the diet therapy of type I diabetes mellitus. Deutsche Medizinische Wochenschrift1986;111(31-32):1220-2. ">Chantelau 1986</a>; <a href="./references#CD012885-bbs2-0019" title="CorfeG . Diabetes treated by saccharine food. BMJ1858;s4-1(58):102-3. ">Corfe 1858</a>; <a href="./references#CD012885-bbs2-0021" title="DinkovskiN . Natural sweetener is suitable for diabetics. www.foodmanufacture.co.uk/Article/2017/05/01/Natural-sweetener-is-suitable-for-diabetics (accessed 25 January 2018). ">Dinkovski 2017</a>; <a href="./references#CD012885-bbs2-0027" title="GapparovMM . Sugar substitutes in specialized child nutrition products for the prevention and treatment of diabetes mellitus. Voprosy Pitaniia1996;5:68-70. ">Gapparov 1996</a>; <a href="./references#CD012885-bbs2-0028" title="HealyAM . Artificial sweeteners and high-fructose corn syrup: effects on diabetes and weight. Integrative Medicine Alert2013;16(10):114-9. ">Healy 2013</a>; <a href="./references#CD012885-bbs2-0029" title="HeraudG , RouxE . Chemical sweeteners in current dietetics applied to diabetic patients. Ouest Medical1976;29(7):503-6. ">Heraud 1976</a>; <a href="./references#CD012885-bbs2-0034" title="MacdonaldI . The therapeutic potential of artificial sweeteners. Practitioner1970;204(220):268-70. ">Macdonald 1970</a>; <a href="./references#CD012885-bbs2-0039" title="MazovetskiiAG . Sugar substitutes in the treatment of diabetes mellitus. Sovetskaia Meditsina1976;6:93-6. ">Mazovetskii 1976</a>; <a href="./references#CD012885-bbs2-0041" title="MehnertH , DietzeG , HaslbeckM . Sugar and sugar substitutes in dietary treatment of disorders of carbohydrate metabolism. Nutrition and Metabolism1975;18(Suppl 1):171-90. ">Mehnert 1975</a>; <a href="./references#CD012885-bbs2-0042" title="MehnertH , FoersterH . Oral administration of fructose as sugar substitute in the diet of diabetes mellitus patients. Aktuelle Ernahrungsmedizin Klinik und Praxis1979;4(4):178-93. ">Mehnert 1979</a>; <a href="./references#CD012885-bbs2-0060" title="PurdyCW . The use of saccharin in diabetes. JAMA1988;259(8):1260. ">Purdy 1988</a>; <a href="./references#CD012885-bbs2-0070" title="SaundbyR . Jambul in diabetes; saccharine in diabetes. Lancet1887;130(3347):834. ">Saundby 1887</a>; <a href="./references#CD012885-bbs2-0075" title="SkylerJS , MillerNE . The use of sweeteners by diabetic patients. Practical Cardiology1980;6(10):119-29. ">Skyler 1980</a>; <a href="./references#CD012885-bbs2-0076" title="SloaneJ . Leicester infirmary: observations on the saccharine treatment of diabetes mellitus. British Medical Journal1858;s4-1(74):425-7. ">Sloane 1858</a>; <a href="./references#CD012885-bbs2-0077" title="StevensHC . Diabetes and diet beverage study has serious limitations. American Journal of Clinical Nutrition2013;98(1):248-9. ">Stevens 2013</a>; <a href="./references#CD012885-bbs2-0078" title="StoyeU , SchmutzE , KrebsS , KochS . Expert advice: Stevia. Zeitschrift fur Phytotherapie2008;29(3):137. ">Stoye 2008</a>; <a href="./references#CD012885-bbs2-0082" title="TuttasK , KirchW . Steviol glycosides as sweetener in diabetes?Deutsche Medizinische Wochenschrift2012;137(15):806. ">Tuttas 2012</a>; <a href="./references#CD012885-bbs2-0084" title="VerspohlEJ . Type 2 diabetes mellitus: importance of sugar and sugar substitutes. Medizinische Monatsschrift fur Pharmazeuten2014;37(5):191-2. ">Verspohl 2014</a>; <a href="./references#CD012885-bbs2-0086" title="WatalG , DharP , SrivastavaSK , SharmaB . Herbal medicine as an alternative medicine for treating diabetes: the global burden. Evidence-based Complementary and Alternative Medicine2014;2014:Article ID 596071. ">Watal 2014</a>; <a href="./references#CD012885-bbs2-0088" title="WilliamsT . Saccharine diet in diabetes. British Medical Journal1858;s4-1(53):18. ">Williams 1858</a>; <a href="./references#CD012885-bbs2-0089" title="WilliamsO . Botanicals in diabetes treatment: a look at stevia. drugtopics.modernmedicine.com/drug-topics/content/tags/diabetes/botanicals-diabetes-treatment-look-stevia?page=full (accessed 27 January 2018). ">Williams 2014</a>; <a href="./references#CD012885-bbs2-0091" title="YlikahriR , PelkonenR . Artificial sweeteners in the diabetic diet. Duodecim1980;96(9):659-62. ">Ylikahri 1980</a>), and a further 11 records due to inappropriate trial design (<a href="./references#CD012885-bbs2-0023" title="FarkasCS , ForbesCE . Do non-caloric sweeteners aid patients with diabetes to adhere to their diets?Journal of the American Dietetic Association1965;46:482-4. ">Farkas 1965</a>; <a href="./references#CD012885-bbs2-0040" title="McCannMB , TrulsonMF , StulbSC . Non-caloric sweeteners and weight reduction. Journal of the American Dietetic Association1956;32(4):327-30. ">McCann 1956</a>; <a href="./references#CD012885-bbs2-0048" title="NCT02813759. Sucralose in subjects with diabetes mellitus insulin requesting (SDMIR). clinicaltrials.gov/ct2/show/record/NCT02813759 (first received 27 June 2016). ">NCT02813759</a>; <a href="./references#CD012885-bbs2-0050" title="NorenE , ForssellH . Very low calorie diet without aspartame in obese subjects: improved metabolic control after 4 weeks treatment. Nutrition Journal2014;13:77. ">Noren 2014</a>; <a href="./references#CD012885-bbs2-0053" title="ParimalavalliR , RadhaisriS . Glycaemic index of stevia product and its efficacy on blood glucose level in type 2 diabetes. Indian Journal of Science and Technology2011;4(3):318-21. ">Parimalavalli 2011</a>; <a href="./references#CD012885-bbs2-0065" title="RituM , NandiniJ . Nutritional composition of Stevia rebaudiana, a sweet herb, and its hypoglycaemic and hypolipidaemic effect on patients with non-insulin dependent diabetes mellitus. Journal of the Science of Food &amp; Agriculture2016;96(12):4231-4. ">Ritu 2016</a>; <a href="./references#CD012885-bbs2-0071" title="SchatzH , WinklerG , PfeifferEF . Sweeteners and sugar exchange foods in the diet of juvenile diabetics. Munchener Medizinische Wochenschrift1977;119(7):213-4. ">Schatz 1977</a>; <a href="./references#CD012885-bbs2-0072" title="SharafetdinovKK , MeshcheriakovaVA , PlotnikovaOA , GapparovMG . Comparative study of postprandial glycaemia in type 2 diabetic patients after consumption of mono- and disaccharides and sweeteners. Voprosy Pitaniia2002;71(2):22-6. ">Sharafetdinov 2002</a>; <a href="./references#CD012885-bbs2-0073" title="ShigetaH , YoshidaT , NakaiM , MoriH , KanoY , NishiokaH , et al. Effects of aspartame on diabetic rats and diabetic patients. Journal of Nutritional Science and Vitaminology1985;31(5):533-40. ">Shigeta 1985</a>; <a href="./references#CD012885-bbs2-0087" title="WilliamsT , LondMD . On the effects of saccharine diet in diabetes mellitus. British Medical Journal1857;s4-1(51):1041-2. ">Williams 1857</a>; <a href="./references#CD012885-bbs2-0090" title="WillsJH , SerroneDM , CoulstonF . A 7-month study of ingestion of sodium cyclamate by human volunteers. Regulatory Toxicology and Pharmacology : RTP1981;1(2):163-76. ">Wills 1981</a>). We excluded 13 records because the duration of the intervention was shorter than four weeks (<a href="./references#CD012885-bbs2-0010" title="ACTRN12618000862246. Do low-calorie sweeteners influence intestinal glucose absorption in patients with type 2 diabetes?www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=375119 (first received 22 May 2018). ">ACTRN12618000862246</a>; <a href="./references#CD012885-bbs2-0014" title="BaturinaBA , SharafetdinovXX , MeshcheriakovaBA , PlotnikovaOA , SokolovAI , GapparovMM . Effect of food additive Neotame (N-[N-(3,3-dimethylbutyl)-L-alpha-aspartyl]-L-phenylalanine-1-methyl) on glucose level in blood of patients with diabetes mellitus type 2. Voprosy Pitaniia2004;73(6):18-20. ">Baturina 2004</a>; <a href="./references#CD012885-bbs2-0020" title="DeschampsI , TichetJ , LestradetH . Influence of cyclamate on blood sugar in normal and diabetic children. Diabete1971;19(1):21-3. ">Deschamps 1971</a>; <a href="./references#CD012885-bbs2-0024" title="FerlandA , BrassardP , PoirierP . Is aspartame really safer in reducing the risk of hypoglycemia during exercise in patients with type 2 diabetes?Diabetes Care2007;30(7):e59. ">Ferland 2007</a>; <a href="./references#CD012885-bbs2-0026" title="FukudaM , TerataT , TsudaK , SugawaraM , KitataniN , SeinoY . Aspartame-acesulfame K-containing low-energy erythritol sweetener markedly suppresses postprandial hyperglycemia in mild and borderline diabetics. Food Science and Technology Research2010;16(5):457-66. ">Fukuda 2010</a>; <a href="./references#CD012885-bbs2-0037" title="MakiKC , CurryLL , McKenneyJM , FarmerMV , ReevesMS , DicklinMR , et al. Glycemic and blood pressure responses to acute doses of rebaudioside A, a steviol glycoside, in subjects with normal glucose tolerance or type 2 diabetes mellitus. FASEB Journal. Conference: Experimental Biology2009;23(1 Suppl):351.6. ">Maki 2009</a>; <a href="./references#CD012885-bbs2-0044" title="NCT01324921. Effect of nutritional products on metabolic parameters in subjects with type 2 diabetics. clinicaltrials.gov/show/NCT01324921 (first received 29 March 2011). ">NCT01324921</a>; <a href="./references#CD012885-bbs2-0049" title="NCT03680482. To compare the effects of non-nutritive sweeteners intake in subjects with T2DM. clinicaltrials.gov/ct2/show/NCT03680482 (first received 21 September 2018). ">NCT03680482</a>; <a href="./references#CD012885-bbs2-0052" title="PACTR201410000894447. Efficacy and cost of stevia rebaudiana bertoni extract as adjunctive therapy in Sahrawi patients with type 2 diabetes. pactr.samrc.ac.za/Search.aspx (accessed 27 January 2018). ">PACTR201410000894447</a>; <a href="./references#CD012885-bbs2-0058" title="ProlsH , HaslbeckM , MehnertH . Investigations into the action of high doses of saccharin on the metabolism in diabetics. Deutsche Medizinische Wochenschrift1973;98(41):1901-4. ">Prols 1973</a>; <a href="./references#CD012885-bbs2-0059" title="PrölsH , WittmannP , HaslbeckM , MehnertH . Investigations on the effect of high sodium cyclamate doses on the metabolism of diabetics. Munchener Medizinische Wochenschrift (1950)1974;116(43):1885-8. ">Pröls 1974</a>; <a href="./references#CD012885-bbs2-0067" title="RogersPJ , BlundellJE . Reanalysis of the effects of phenylalanine, alanine, and aspartame on food intake in human subjects. Physiology &amp; Behavior1994;56(2):247-50. ">Rogers 1994</a>; <a href="./references#CD012885-bbs2-0085" title="VorsterHH , vanTonderE , KotzeJP , WalkerAR . Effects of graded sucrose additions on taste preference, acceptability, glycemic index, and insulin response to butter beans. American Journal of Clinical Nutrition1987;45(3):575-9. ">Vorster 1987</a>); in four trials the intervention was unclear (<a href="./references#CD012885-bbs2-0030" title="IRCT2015091513612N6. Comparison of glycemic control in patients with type 2 diabetes on regular diabetic diet or artificial sweeteners. apps.who.int/trialsearch/Trial3.aspx?trialid=IRCT2015091513612N6 (accessed 14 January 2019). ">IRCT2015091513612N6</a>; <a href="./references#CD012885-bbs2-0035" title="MadjdA , TaylorMA , DelavariA , MalekzadehR , MacdonaldIA , FarshchiHR . Beneficial effects of replacing diet beverages with water on type 2 diabetic obese women following a hypo-energetic diet: a randomized, 24-week clinical trial. Diabetes, Obesity &amp; Metabolism2017;19(1):125-32. ">Madjd 2017</a>; <a href="./references#CD012885-bbs2-0046" title="NCT02412774. Effects of replacing diet beverages with water on weight loss and plasma glucose control in type 2 diabetes. clinicaltrials.gov/ct2/show/NCT02412774 (first received 9 April 2015). ">NCT02412774</a>; <a href="./references#CD012885-bbs2-0051" title="OdegaardA , HirahatakeK . The effect of diet beverage intake on measures of diabetes control: a pilot study. Circulation 2017 March 7;135(Suppl 1):AP293. ">Odegaard 2017</a>); whilst in another four trials the intervention was not an NNS (<a href="./references#CD012885-bbs2-0064" title="ReynaNY , CanoC , BermudezVJ , MedinaMT , SoukiAJ , AmbardM , et al. Sweeteners and beta-glucans improve metabolic and anthropometrics variables in well controlled type 2 diabetic patients. American Journal of Therapeutics2003;10(6):438-43. ">Reyna 2003</a>; <a href="./references#CD012885-bbs2-0068" title="SadeghiF , SalehiS , KohanmooA , AkhlaghiM . Effect of natural honey on glycemic control and anthropometric measures of patients with type 2 diabetes: a randomized controlled crossover trial. International Journal of Preventive Medicine2019;10:3. ">Sadeghi 2019</a>; <a href="./references#CD012885-bbs2-0069" title="SamantaA , BurdenAC , JonesGR . Plasma glucose responses to glucose, sucrose, and honey in patients with diabetes mellitus: an analysis of glycaemic and peak incremental indices. Diabetic Medicine1985;2(5):371-3. ">Samanta 1985</a>; <a href="./references#CD012885-bbs2-0074" title="SimeonovSB , BotushanovNP , KarahanianEB , PavlovaMB , HusianitisHK , TroevDM . Effects of Aronia melanocarpa juice as part of the dietary regimen in patients with diabetes mellitus. Folia Medica (Plovdiv)2002;44(3):20-3. ">Simeonov 2002</a>). One trial described in a registry entry was never started based on information from the authors (<a href="./references#CD012885-bbs2-0022" title="EUCTR2006-002395-18-DK. Intervention studier med steviol til belysning af dosis respons forhold samt langtidseffekt hos personer med type 2 diabetes. www.clinicaltrialsregister.eu/ctr-search/trial/2006-002395-18/DK (accessed 3 August 2018). ">EUCTR2006‐002395‐18‐DK</a>). </p> <p>We excluded 23 records describing trials that did not include participants of relevance for this review (<a href="./references#CD012885-bbs2-0016" title="BlackburnGL , KandersBS , LavinPT , KellerSD , WhatleyJ . The effect of aspartame as part of a multidisciplinary weight-control program on short- and long-term control of body weight. American Journal of Clinical Nutrition1997;65(2):409-18. ">Blackburn 1997</a>; <a href="./references#CD012885-bbs2-0025" title="FerriLA , Alves-Do-PradoW , YamadaSS , GazolaS , BatistaMR , BazotteRB . Investigation of the antihypertensive effect of oral crude stevioside in patients with mild essential hypertension. Phytotherapy Research2006;20(9):732-6. ">Ferri 2006</a>; <a href="./references#CD012885-bbs2-0031" title="KandersBS , LavinPT , KowalchukMB , GreenbergI , BlackburnGL . An evaluation of the effect of aspartame on weight loss. Appetite1988;11 Suppl 1:73-84. ">Kanders 1988</a>; <a href="./references#CD012885-bbs2-0032" title="KnoppRH , BrandtK , ArkyRA . Effects of aspartame in young persons during weight reduction. Journal of Toxicology and Environmental Health1976;2(2):417-28. ">Knopp 1976</a>; <a href="./references#CD012885-bbs2-0033" title="LeonAS , HunninghakeDB , BellC , RassinDK , TephlyTR . Safety of long-term large doses of aspartame. Archives of Internal Medicine1989;149(10):2318-24. ">Leon 1989</a>; <a href="./references#CD012885-bbs2-0036" title="MaerskM , BelzaA , Stødkilde-JørgensenH , RinggaardS , ChabanovaE , ThomsenH , et al. Sucrose-sweetened beverages increase fat storage in the liver, muscle, and visceral fat depot: a 6-mo randomized intervention study. American Journal of Clinical Nutrition2012;95(2):283-9. ">Maersk 2012</a>; <a href="./references#CD012885-bbs2-0038" title="MasicU , HarroldJA , ChristiansenP , CuthbertsonDJ , HardmanCA , RobinsonE , et al. Effects of non-nutritive sweetened beverages on appetite during active weight loss (SWITCH): protocol for a randomized, controlled trial assessing the effects of non-nutritive sweetened beverages compared to water during a 12-week weight loss period and a follow up weight maintenance period. Contemporary Clinical Trials2017;53:80-8. ">Masic 2017</a>; <a href="./references#CD012885-bbs2-0043" title="MorrisDH , CuneoP , StuartMJ , ManceMJ , BellKJ , PuleoE , et al. High-intensity sweetener, energy and nutrient intakes of overweight women and men participating in a weight-loss program. Nutrition Research (New York, NY)1993;13(2):123-32. ">Morris 1993</a>; <a href="./references#CD012885-bbs2-0045" title="NCT02252952. The effect of sugar sweetened and diet beverages consumed as part of a weight-maintenance diet on fat storage. clinicaltrials.gov/ct2/show/NCT02252952 (first received 30 September 2014). ">NCT02252952</a>; <a href="./references#CD012885-bbs2-0047" title="NCT02487537. Immediate and long-term induction of incretin release by artificial sweeteners 2 (ILIAS-2). clinicaltrials.gov/show/NCT02487537 (first received 1 July 2015). ">NCT02487537</a>; <a href="./references#CD012885-bbs2-0054" title="PetersJC , WyattHR , FosterGD , PanZ , WojtanowskiAC , Vander VeurSS , et al. The effects of water and non-nutritive sweetened beverages on weight loss during a 12-week weight loss treatment program. Obesity (Silver Spring, MD)2014;22(6):1415-21. ">Peters 2014</a>; <a href="./references#CD012885-bbs2-0055" title="PetersJC , BeckJ , CardelM , WyattHR , FosterGD , PanZ , et al. The effects of water and non-nutritive sweetened beverages on weight loss and weight maintenance: a randomized clinical trial. Obesity (Silver Spring, MD)2016;24(2):297-304. ">Peters 2016</a>; <a href="./references#CD012885-bbs2-0056" title="PiernasC , TateDF , PopkinBM . Does diet beverage intake affect consumption patterns? Results from the choice RCT study. Obesity (Silver Spring, MD)2011;19:S70. ">Piernas 2011</a>; <a href="./references#CD012885-bbs2-0057" title="PiernasC , TateDF , WangX , PopkinBM . Does diet-beverage intake affect dietary consumption patterns? Results from the Choose Healthy Options Consciously Everyday (CHOICE) randomized clinical trial. American Journal of Clinical Nutrition2013;97(3):604-11. ">Piernas 2013</a>; <a href="./references#CD012885-bbs2-0061" title="ReidM , HammersleyR . The effects of sucrose on everyday eating in normal weight men and women. Appetite1994;22(3):221-31. ">Reid 1994</a>; <a href="./references#CD012885-bbs2-0062" title="ReidM , HammersleyR . The effects of sugar on subsequent eating and mood in obese and non-obese women. Psychology, Health &amp; Medicine1998;3(3):299-313. ">Reid 1998</a>; <a href="./references#CD012885-bbs2-0063" title="ReidM , HammersleyR , DuffyM . Effects of sucrose drinks on macronutrient intake, body weight, and mood state in overweight women over 4 weeks. Appetite2010;55(1):130-6. ">Reid 2010</a>; <a href="./references#CD012885-bbs2-0066" title="RodinJ . Comparative effects of fructose, aspartame, glucose, and water preloads on calorie and macronutrient intake. American Journal of Clinical Nutrition1990;51(3):428-35. ">Rodin 1990</a>; <a href="./references#CD012885-bbs2-0079" title="SørensenLB , VasilarasTH , AstrupA , RabenA . Sucrose compared with artificial sweeteners: a clinical intervention study of effects on energy intake, appetite, and energy expenditure after 10 wk of supplementation in overweight subjects. American Journal of Clinical Nutrition2014;100(1):36-45. ">Sørensen 2014</a>; <a href="./references#CD012885-bbs2-0080" title="TaljaardC , CovicNM , vanGraanAE , KrugerHS , SmutsCM , BaumgartnerJ , et al. Effects of a multi-micronutrient-fortified beverage, with and without sugar, on growth and cognition in South African schoolchildren: a randomised, double-blind, controlled intervention. British Journal of Nutrition2013;110(12):2271-84. ">Taljaard 2013</a>; <a href="./references#CD012885-bbs2-0081" title="TsapokPI , ImbriakovKV , ChuchkovaMR . Sugar substitute products impact on oral fluid biochemical properties. Stomatologiia2012;91(2):23-5. ">Tsapok 2012</a>; <a href="./references#CD012885-bbs2-0083" title="Vazquez DuranM , Castillo MartinezL , Orea TejadaA , Tellez OlveraDA , Delgado PerezLG , Marquez ZepedaB , et al. Effect of decreasing the consumption of sweetened caloric and non-caloric beverages on weight, body composition and blood pressure in young adults. European Journal of Preventive Cardiology2013;20(1 Suppl 1):S120. ">Vazquez Duran 2013</a>; <a href="./references#CD012885-bbs2-0092" title="ZöllnerN , PieperM . Concluding report of a 3-year clinical study on cyclamate. Arzneimittel-Forschung1971;21(3):431-2. ">Zöllner 1971</a>). </p> </section> </section> <section id="CD012885-sec-0070"> <h3 class="title">Risk of bias in included studies</h3> <p>For details on the risk of bias of included trials, see <a href="./references#CD012885-sec-0170" title="">Characteristics of included studies</a>. </p> <p>For an overview of review authors' judgements about each 'Risk of bias' item for individual trials and across all trials, see <a href="#CD012885-fig-0002">Figure 2</a> and <a href="#CD012885-fig-0003">Figure 3</a>. </p> <div class="figure" id="CD012885-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012885-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> </div> <div class="figure" id="CD012885-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials)" data-id="CD012885-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-03.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials) </p> </div> </div> </div> <section id="CD012885-sec-0071"> <h4 class="title">Allocation</h4> <p>We judged only one trial as at low risk of selection bias regarding the method of both randomisation and allocation concealment (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). For another trial we were able to retrieve information on participant selection by contacting the authors; based on this information we judged the method used for generating random sequence to be at low risk of bias, whilst allocation, which was done in an open manner, was judged as at high risk of bias (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). The remaining seven trials reported only that participants were randomised without providing any further description either on random sequence generation or on allocation concealment (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), and were therefore judged as at unclear risk of bias for both domains. </p> <p>Key prognostic variables (age, gender, BMI, ethnicity, comorbidities including hypertension and cardiovascular disease) were balanced between the intervention groups at baseline, but were not reported in all trials (see <a href="./appendices#CD012885-sec-0147">Appendix 6</a>; <a href="./appendices#CD012885-sec-0148">Appendix 7</a>). </p> </section> <section id="CD012885-sec-0072"> <h4 class="title">Blinding</h4> <p>There was one open‐label trial, which we judged as at high risk of bias for blinding of participants and personnel for the outcome measures body weight and glucose levels (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). All of the other included trials explicitly reported blinding of participants and personnel (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), which was ensured by using placebo, <a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>, or by identical packing, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>, and similar taste of the intervention substance (<a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>). Outcome assessment was less well described across trials, with none of the nine trials providing clear information on blinding of outcome assessors. </p> <p>Measurements of HbA1c were investigator assessed in all trials where this outcome was measured, and since HbA1c is an objective laboratory measure, we judged performance bias as at low risk even in the trial where participants and personnel were not blinded (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). For the same reason, we judged detection bias as at low risk in all seven reporting trials. </p> <p>Where measured, body weight was investigator assessed. Amongst trials reporting body weight, we judged six trials with a double‐blind design as at low risk of performance bias (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), and one trial with a lack of blinding as at high risk of performance bias (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). As in general there was no information on the blinding of outcome assessors, we judged trials reporting body weight as at unclear risk of detection bias (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). We received additional information from the authors of one study stating that body weight was measured independently by personnel unrelated to the study, therefore we judged detection bias for this study as at low risk (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). </p> <p>Adverse events were reported in four trials and were always self‐reported by participants. As participants were adequately blinded in trials reporting adverse events, we judged both performance and detection bias as at low risk in these trials (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). </p> </section> <section id="CD012885-sec-0073"> <h4 class="title">Incomplete outcome data</h4> <p>Six trials reported the numbers of participants randomised to each intervention/comparator group as well as those who finished the trials (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). The proportion of randomised participants completing these trials per protocol varied from 41.3%, in <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>, to 100%, in <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>. The remaining three trials did not report on the number of participants randomised to each intervention/comparator group, only the total number of participants randomised and the number of participants finalising the study (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). One trial did not clearly report the number of participants analysed (<a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). </p> <p>Three trials clearly reported the number of participant losses (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). In one of the trials, the study authors stated that discontinuations did not happen as a consequence of an adverse event, but did not provide further details (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>). In one trial reasons for discontinuations included: withdrawal of consent (one), protocol violation (one), personal reasons (one), and adverse events (three) (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). In the third trial there was only one dropout, and the reason was an adverse event (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). </p> <p>Eight trials reported data for HbA1c. In two trials HbA1c data were reported for all randomised participants (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>), whilst in one trial imputed data were balanced in numbers across groups (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>); we judged these trials reporting on HbA1c to be at low risk of attrition bias. In one trial dropout rates were reported for both groups without a detailed description of reasons (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>), whilst in another trial it was unclear whether there were any dropouts (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>). In a further trial, HbA1c data were reported only for participants completing the trial (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). We judged these trials as at unclear risk of attrition bias for the outcome HbA1c. In two trials with high dropout rates reasons for attrition were not reported (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>), therefore these trials were judged as at high risk of attrition bias for the outcome HbA1c. </p> <p>Seven trials collected data for body weight. Three trials reported data on body weight for all randomised participants and were judged to be at low risk of bias (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). We assessed two trials as at unclear risk of attrition bias either because it was unclear whether there were any dropouts, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>, or because reasons for attrition were not reported in a trial with low dropout rates, <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>. In one trial with high dropout rates, data on body weight and numbers of and reasons for missing body weight data were not reported (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>), therefore we judged this trial as at high attrition bias for the outcome body weight. One further trial with high dropout rates mentioned that body weight of participants was measured, but data for body weight (kg) were not provided (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>). </p> <p>Three trials reported adverse events in detail (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). In one trial, adverse events were not reported, but were described to be balanced across groups (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>); we judged this trial as at low risk of attrition bias for this outcome. In one study the numbers of and reasons for participant losses due to adverse events were unclear (<a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). </p> <p>None of the trials performed an intention‐to‐treat analysis.</p> </section> <section id="CD012885-sec-0074"> <h4 class="title">Selective reporting</h4> <p>We did not find published protocols for any of the included trials. We judged five trials to be at low risk of reporting bias according to the Outcome Reporting Bias In Trials (ORBIT) classification, because it appeared that all expected outcomes had been reported (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>; <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>). We judged four trials to be at high risk of reporting bias: in one of these trials it was described in the methods that weight and waist circumference were measured, but values were not reported (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>); in another trial body weight and BMI were measured but data were not reported (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>); in a further trial the outcomes HbA1c, fasting glucose, and adverse events were reported incompletely (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>); and in the fourth trial body weight and glucose levels were reported in a selective way (<a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). For more details, see <a href="./appendices#CD012885-sec-0150">Appendix 9</a>; <a href="./appendices#CD012885-sec-0151">Appendix 10</a>. </p> </section> <section id="CD012885-sec-0075"> <h4 class="title">Other potential sources of bias</h4> <p>As potential other sources of bias we evaluated the presence of industry sponsorship (<a href="./references#CD012885-bbs2-0141" title="LundhA , LexchinJ , MintzesB , SchrollJB , BeroL . Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.MR000033.pub3]">Lundh 2017</a>), and for cross‐over studies whether the trial could be biased from carry‐over effects (<a href="./references#CD012885-bbs2-0128" title="HigginsJP , LiT , Deeks JJ (editors). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane Handbook for Systematic Reviews of Interventions version 6.0 (updated July 2019). Cochrane, 2019. Available from www.training.cochrane.org/handbook.">Higgins 2019a</a>). In one trial investigators declared that they had received products used for supplementation from industry (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>); in four trials study authors provided a general statement about industry funding (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>); and in one study it was unclear if industry funding had been received (<a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>); we judged all of these studies to be at unclear risk of bias. One trial had a cross‐over design without a washout period between the two intervention periods (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>), and two trials described both industry funding and cross‐over design without washout period (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>); we judged these trials to be at high risk of bias. </p> </section> </section> <section id="CD012885-sec-0076"> <h3 class="title" id="CD012885-sec-0076">Effects of interventions</h3> <p>See: <a href="./full#CD012885-tbl-0001"><b>Summary of findings 1</b> Non‐nutritive sweeteners for diabetes mellitus</a> </p> <p>For a summary of the evidence, see <a href="./full#CD012885-tbl-0001">summary of findings Table 1</a>. </p> <section id="CD012885-sec-0077"> <h4 class="title">Baseline characteristics</h4> <p>For details of baseline characteristics, see <a href="./appendices#CD012885-sec-0147">Appendix 6</a>; <a href="./appendices#CD012885-sec-0148">Appendix 7</a>. </p> </section> <section id="CD012885-sec-0078"> <h4 class="title">Any type of NNS, either alone or in combination with another NNS, versus sugar (i.e. usual diet containing sugar or diet containing sugar with additional sugar as supplement) </h4> <p>We identified three trials comparing the health effects of a NNS with sugar. In two trials NNS were added to the usual diet (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>), whilst in the third study participants were instructed to consume either NNS or sucrose ad libitum, and the consumed amounts were measured (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). NNS used were aspartame (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>), saccharin (<a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>), or sodium‐cyclamate (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). The duration of intervention ranged from four weeks, <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, to six weeks, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>. </p> <p>Two of the trials involved participants with type 2 diabetes (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>), whilst one trial involved participants with type 1 diabetes (<a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>). </p> <p>All three trials had a cross‐over design and were reporting data for the first and second periods together. None of the three trials described a washout period. </p> <section id="CD012885-sec-0079"> <h5 class="title">Primary outcomes</h5> <section id="CD012885-sec-0080"> <h6 class="title">HbA1c</h6> <p>Three trials compared the effects of NNS as compared to sugar on HbA1c, including overall 72 participants (random‐effects mean difference (MD) 0.4%, 95% confidence interval (CI) −0.5 to 1.2; fixed‐effect MD 0.4%, 95% CI 0.1 to 0.7; P = 0.44; 3 trials; 72 participants; very low‐certainty evidence; <a href="./references#CD012885-fig-0007" title="">Analysis 1.1</a>). There was considerable heterogeneity (I² = 86%), likely caused by the combination of cross‐over study design, low number of participants, short intervention period, and no washout period between interventions. The 95% prediction interval did not provide a meaningful estimate. </p> <p>Due to the short, <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, or missing, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>, run‐in periods and short intervention duration lasting only four, <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, to six weeks, <a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a>, carry‐over effects and effects of the consumption before the study start might have had a considerable impact on results. </p> </section> <section id="CD012885-sec-0081"> <h6 class="title">Body weight (kg)</h6> <p>Three trials reported weight change (MD −0.1 kg, 95% CI −2.7 to 2.6; P = 0.96; 3 trials; 72 participants; very low‐certainty evidence; <a href="./references#CD012885-fig-0008" title="">Analysis 1.2</a>). </p> </section> <section id="CD012885-sec-0082"> <h6 class="title">Adverse events</h6> <p>None of the trials reported on non‐serious or serious adverse events.</p> </section> </section> <section id="CD012885-sec-0083"> <h5 class="title">Secondary outcomes</h5> <section id="CD012885-sec-0084"> <h6 class="title">Diabetes complications</h6> <p>None of the trials reported on diabetes complications.</p> </section> <section id="CD012885-sec-0085"> <h6 class="title">All‐cause mortality</h6> <p>None of the trials reported on all‐cause mortality.</p> </section> <section id="CD012885-sec-0086"> <h6 class="title">Health‐related quality of life</h6> <p>None of the trials reported on health‐related quality of life.</p> </section> <section id="CD012885-sec-0087"> <h6 class="title">Anthropometric measures other than body weight (kg)</h6> <p>None of the trials reported on anthropometric measures other than body weight.</p> </section> <section id="CD012885-sec-0088"> <h6 class="title">Lipid profile</h6> <p>Three trials reported total cholesterol (MD −0.8 mg/dL, 95% CI −11.1 to 9.6; P = 0.88; 3 trials; 72 participants; <a href="./references#CD012885-fig-0009" title="">Analysis 1.3</a>). Three trials reported HDL cholesterol (MD −1.1 mg/dL, 95% CI −5.6 to 3.4; P = 0.64; 3 trials; 72 participants; <a href="./references#CD012885-fig-0010" title="">Analysis 1.4</a>). One trial reported LDL cholesterol (MD 1.2 mg/dL, 95% CI −15.6 to 18; 1 trial; 34 participants; <a href="./references#CD012885-fig-0011" title="">Analysis 1.5</a>). Three trials reported triglycerides (MD −1.5 mg/dL, 95% CI −15 to 11.9; P = 0.82; 3 trials; 72 participants; <a href="./references#CD012885-fig-0012" title="">Analysis 1.6</a>). </p> </section> <section id="CD012885-sec-0089"> <h6 class="title">Glucose levels (fasting and postprandial)</h6> <p>Two trials reported fasting blood glucose levels (MD −5.0 mg/dL, 95% CI −28.3 to 18.3; P = 0.67; 2 trials; 52 participants; <a href="./references#CD012885-fig-0013" title="">Analysis 1.7</a>). One trial reported postprandial blood glucose levels (MD 11.9 mg/dL, 95% CI −20.7 to 44.5; 1 trial; 20 participants; <a href="./references#CD012885-fig-0014" title="">Analysis 1.8</a>). </p> </section> <section id="CD012885-sec-0090"> <h6 class="title">Serum insulin</h6> <p>One trial reported serum insulin levels (MD 0.8 microunits/mL, 95% CI −2.8 to 4.4; 1 trial; 34 participants; <a href="./references#CD012885-fig-0015" title="">Analysis 1.9</a>). </p> </section> <section id="CD012885-sec-0091"> <h6 class="title">Insulin sensitivity</h6> <p>None of the trials reported on insulin sensitivity.</p> </section> <section id="CD012885-sec-0092"> <h6 class="title">Socioeconomic effects</h6> <p>None of the trials reported on socioeconomic effects.</p> </section> </section> </section> <section id="CD012885-sec-0093"> <h4 class="title">Any type of NNS, either alone or in combination with another NNS, versus no intervention</h4> <p>We identified no trials comparing NNS with no intervention.</p> </section> <section id="CD012885-sec-0094"> <h4 class="title">Any type of NNS, either alone or in combination with another NNS, versus placebo</h4> <p>We identified five trials comparing the health effects of an NNS with placebo. In all of these trials both NNS and placebo were added as a dietary supplement (in the form of capsules) to the usual diet. Two trials added <i>Stevia rebaudiana</i>‐based products, one in the form of steviol glycoside capsules (250 mg three times a day for 3 months) (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>), and the other as rebaudioside A (250 mg capsules four times a day for 16 weeks) (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). The capsules differed slightly in the purity of stevia content (92% purity in the first study and 97% in the second study). One study compared the effects of sucralose (667 mg daily in capsules for 13 weeks) with placebo (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>), whilst two trials investigated aspartame as the intervention (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), with an intervention duration of 18 and 13 weeks and a daily dose of 2.7 g and 1.8 g, respectively. </p> <p>For this comparison, three trials evaluated participants with type 2 diabetes (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>; <a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>; <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>), one study both participants with type 1 and type 2 diabetes (<a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>); and one study both participants with type 1 and type 2 diabetes, however these were analysed as separate study groups (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>). </p> <section id="CD012885-sec-0095"> <h5 class="title">Primary outcomes</h5> <section id="CD012885-sec-0096"> <h6 class="title">HbA1c</h6> <p>Of the four trials comparing NNS with placebo, two trials provided data as final value scores and two as change‐from‐baseline scores. NNS had no substantial effect on HbA1c (MD 0%, 95% CI −0.1 to 0.1; P = 0.99; 4 trials; 360 participants; very low‐certainty evidence; <a href="./references#CD012885-fig-0016" title="">Analysis 2.1</a>; <a href="#CD012885-fig-0004">Figure 4</a>). The 95% prediction interval ranged between −0.3% and 0.3%. </p> <div class="figure" id="CD012885-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 NNS versus placebo, outcome: 2.1 HbA1c (%)." data-id="CD012885-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-04.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 NNS versus placebo, outcome: 2.1 HbA1c (%).</p> </div> </div> </div> </section> <section id="CD012885-sec-0097"> <h6 class="title">Body weight (kg)</h6> <p>Two trials reported data on body weight: one of them reported data as change from baseline to the average of values at weeks 12 and 16, with baseline defined as the average of values at weeks −2 and 0 (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>), whilst the other reported mean (standard error) values for baseline and week 13 (<a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). Comparing NNS with placebo showed an MD in body weight of −0.2 kg, 95% CI −1 to 0.6; P = 0.64; 2 trials; 184 participants; <a href="./references#CD012885-fig-0017" title="">Analysis 2.2</a>; <a href="#CD012885-fig-0005">Figure 5</a>. </p> <div class="figure" id="CD012885-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 NNS versus placebo, outcome: 2.2 Body weight (kg)." data-id="CD012885-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-05.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 NNS versus placebo, outcome: 2.2 Body weight (kg).</p> </div> </div> </div> </section> <section id="CD012885-sec-0098"> <h6 class="title">Adverse events</h6> <p>Three trials reported the numbers of participants experiencing at least one non‐serious adverse event, with a total of 36/113 participants (31.9%) in the NNS group versus 42/118 participants (35.6%) in the placebo group having a non‐serious adverse event (risk ratio (RR) 0.78, 95% CI 0.39 to 1.56; P = 0.48; 3 trials; 231 participants; very low‐certainty evidence; <a href="./references#CD012885-fig-0018" title="">Analysis 2.3</a>; <a href="#CD012885-fig-0006">Figure 6</a>). The 95% prediction interval did not provide a meaningful estimate. </p> <div class="figure" id="CD012885-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 2 NNS versus placebo, outcome: 2.3 Adverse events (n/N)." data-id="CD012885-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-06.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 2 NNS versus placebo, outcome: 2.3 Adverse events (n/N).</p> </div> </div> </div> <p>Two further trials only narratively reported on adverse events. One of these trials provided the incidence of experienced symptoms, reporting that "mild gastrointestinal complaints were the most common discomforts observed" (<a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>). The other trial only mentioned that "there were no significant differences between the treatment groups in type, number, or severity of adverse events reported" (<a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a>). </p> <p>Two trials reported on serious adverse events (<a href="./appendices#CD012885-sec-0153">Appendix 12</a>): no serious adverse events occurred in one study (<a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a>), and 4/60 and 3/62 serious adverse events occurred in the NNS and placebo groups, respectively, in the other trial (<a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a>). </p> </section> </section> <section id="CD012885-sec-0099"> <h5 class="title">Secondary outcomes</h5> <section id="CD012885-sec-0100"> <h6 class="title">Diabetes complications</h6> <p>None of the trials reported on diabetes complications.</p> </section> <section id="CD012885-sec-0101"> <h6 class="title">All‐cause mortality</h6> <p>None of the trials reported on all‐cause mortality.</p> </section> <section id="CD012885-sec-0102"> <h6 class="title">Health‐related quality of life</h6> <p>None of the trials reported on health‐related quality of life.</p> </section> <section id="CD012885-sec-0103"> <h6 class="title">Anthropometric measures other than body weight (kg)</h6> <p><a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a> reported on BMI (MD −0.4 kg/m², 95% CI −3 to 2.2; P = 0.76; 1 trial; 46 participants; <a href="./references#CD012885-fig-0019" title="">Analysis 2.4</a>). </p> </section> <section id="CD012885-sec-0104"> <h6 class="title">Lipid profile</h6> <p>Three trials reported total cholesterol, two of them with final value scores and one as change‐from‐baseline scores (MD 2 mg/dL, 95% CI −4.8 to 8.8; P = 0.57; 3 trials; 228 participants; <a href="./references#CD012885-fig-0020" title="">Analysis 2.5</a>). Two trials reported HDL cholesterol, one of them providing data as final value scores and one as change‐from‐baseline scores (MD −0.4 mg/dL, 95% CI −2.2 to 1.4; P = 0.67; 2 trials; 168 participants; <a href="./references#CD012885-fig-0021" title="">Analysis 2.6</a>). Two trials reported LDL cholesterol, one of them with providing data as final value scores and one as change‐from‐baseline scores (3.1 mg/dL, 95% CI −2.9 to 9.1; P = 0.31; 2 trials; 168 participants; <a href="./references#CD012885-fig-0022" title="">Analysis 2.7</a>). Two trials reported triglycerides, both of them providing data as final value scores (MD 18.5 mg/dL, 95% CI −6.8 to 43.7; P = 0.15; 2 trials; 106 participants; <a href="./references#CD012885-fig-0023" title="">Analysis 2.8</a>). </p> </section> <section id="CD012885-sec-0105"> <h6 class="title">Glucose levels (fasting and postprandial)</h6> <p>Five trials reported fasting blood glucose levels, four of them providing data as final value scores and one as change‐from‐baseline scores (MD 2.2 mg/dL, 95% CI −11.6 to 16.1; P = 0.75; 5 trials; 384 participants; <a href="./references#CD012885-fig-0024" title="">Analysis 2.9</a>). One trial reported postprandial blood glucose levels (MD −1.1 mg/dL, 95% CI −55.1 to 53.1; P = 0.97; 1 trial; 62 participants; <a href="./references#CD012885-fig-0025" title="">Analysis 2.10</a>). </p> </section> <section id="CD012885-sec-0106"> <h6 class="title">Serum insulin</h6> <p>Two trials reported serum insulin levels, one reporting data as final value scores and one as change‐from‐baseline scores (MD −2.5 microunits/mL, 95% CI −5.4 to 0.4; 2 trials; 152 participants; <a href="./references#CD012885-fig-0026" title="">Analysis 2.11</a>). </p> </section> <section id="CD012885-sec-0107"> <h6 class="title">Insulin sensitivity</h6> <p>None of the trials reported on insulin sensitivity.</p> </section> <section id="CD012885-sec-0108"> <h6 class="title">Socioeconomic effects</h6> <p>None of the trials reported on socioeconomic effects.</p> </section> </section> </section> <section id="CD012885-sec-0109"> <h4 class="title">Any type of NNS, either alone or in combination with another NNS, versus water</h4> <p>We identified no trials comparing NNS with water.</p> </section> <section id="CD012885-sec-0110"> <h4 class="title">Any type of NNS, either alone or in combination with another NNS, versus NNS of a different dose </h4> <p>We identified no trials comparing NNS with a different dose of NNS.</p> </section> <section id="CD012885-sec-0111"> <h4 class="title">Any type of NNS, either alone or in combination with another NNS, versus a nutritive (low‐calorie) sweetener </h4> <p>One trial compared the effects of NNS alone (sucralose 1.5 g, three times a day, dissolved in 125 mL to 250 mL of water) with a nutritive, low‐calorie sweetener (tagatose 15 g, three times a day, dissolved in 125 mL to 250 mL of water) (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>), with an intervention duration of 10 months. The trial included participants with type 2 diabetes. </p> <section id="CD012885-sec-0112"> <h5 class="title">Primary outcomes</h5> <section id="CD012885-sec-0113"> <h6 class="title">HbA1c</h6> <p>One trial reported HbA1c (MD 0.3%, 95% CI 0.1 to 0.4; P = 0.01; 1 trial; 354 participants; very low‐certainty evidence; <a href="./references#CD012885-fig-0027" title="">Analysis 3.1</a> in favour of the nutritive (low‐calorie) sweetener). </p> </section> <section id="CD012885-sec-0114"> <h6 class="title">Body weight (kg)</h6> <p>One trial measured body weight, but data were not reported. It was only stated that "there was no observed effect of D‐tagatose on changes on body weight" compared to the NNS group. </p> </section> <section id="CD012885-sec-0115"> <h6 class="title">Adverse events</h6> <p>The trial stated that adverse events were assessed, but the number of participants and types of adverse events were not reported. </p> </section> </section> <section id="CD012885-sec-0116"> <h5 class="title">Secondary outcomes</h5> <section id="CD012885-sec-0117"> <h6 class="title">Diabetes complications</h6> <p>One trial did not report data on diabetes complications.</p> </section> <section id="CD012885-sec-0118"> <h6 class="title">All‐cause mortality</h6> <p>One trial did not report data on all‐cause mortality.</p> </section> <section id="CD012885-sec-0119"> <h6 class="title">Health‐related quality of life</h6> <p>One trial did not report data on health‐related quality of life.</p> </section> <section id="CD012885-sec-0120"> <h6 class="title">Anthropometric measures other than body weight (kg)</h6> <p>One trial assessed BMI narratively, stating that there were no significant differences between the sucralose and the tagatose groups. </p> </section> <section id="CD012885-sec-0121"> <h6 class="title">Lipid profile</h6> <p><a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a> reported on total cholesterol (MD 1 mg/dL, 95% CI −5.1 to 7.1; P = 0.75; 1 trial; 354 participants; <a href="./references#CD012885-fig-0028" title="">Analysis 3.2</a>); HDL cholesterol (MD 1.3 mg/dL, 95% CI −0.3 to 2.8; P = 0.11; 1 trial; 354 participants; <a href="./references#CD012885-fig-0029" title="">Analysis 3.3</a>); LDL cholesterol (MD 3 mg/dL, 95% CI −2.5 to 8.5; P = 0.29; 1 trial; 354 participants; <a href="./references#CD012885-fig-0030" title="">Analysis 3.4</a>); and triglycerides (MD −22 mg/dL, 95% CI −44.9 to 0.9; P = 0.06; 1 trial; 354 participants; <a href="./references#CD012885-fig-0031" title="">Analysis 3.5</a>). </p> </section> <section id="CD012885-sec-0122"> <h6 class="title">Glucose levels (fasting and postprandial)</h6> <p>One trial reported fasting blood glucose levels (MD 6.50 mg/dL, 95% CI −0.79 to 13.79; P = 0.08; 1 trial; 354 participants; <a href="./references#CD012885-fig-0032" title="">Analysis 3.6</a>). </p> </section> <section id="CD012885-sec-0123"> <h6 class="title">Serum insulin</h6> <p>One trial reported serum insulin concentrations narratively, stating that "there was no detectable consistent change in serum insulin concentrations (<a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>)". </p> </section> <section id="CD012885-sec-0124"> <h6 class="title">Insulin sensitivity</h6> <p>One trial did not report data on insulin sensitivity.</p> </section> <section id="CD012885-sec-0125"> <h6 class="title">Socioeconomic effects</h6> <p>One trial did not report data on socioeconomic effects.</p> </section> </section> </section> <section id="CD012885-sec-0126"> <h4 class="title">Any type of NNS, either alone or in combination with another NNS, plus a behaviour‐changing intervention such as diet, exercise, or both versus any of the comparators (usual diet, no intervention, placebo, water, a different NNS, NNS of a different dose, another type of sweetener) </h4> <p>We identified no trials comparing NNS combined with a behaviour‐changing intervention versus a comparator of interest. </p> </section> <section id="CD012885-sec-0127"> <h4 class="title">Subgroup analyses</h4> <p>We did not perform subgroup analyses because there were not enough trials to estimate effects in various subgroups. </p> </section> <section id="CD012885-sec-0128"> <h4 class="title">Sensitivity analyses</h4> <p>We could not perform a sensitivity analysis for published trials versus unpublished trials because all available data originated from published trials. Sensitivity analyses for risk of bias were not meaningful because of the low number of studies investigating the same comparisons and outcomes and due to the diversity in follow‐up periods. We could not perform sensitivity analysis excluding large trials because none of the included trials had more than 1000 participants randomised to each intervention group. There were also no long‐term trials with a follow‐up period of six months or more, therefore a sensitivity analysis for long‐term trials was not possible. Diagnostic criteria were described in only three trials (<a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a>; <a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a>; <a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a>), which had different comparison groups, therefore a sensitivity analysis for diagnostic criteria was not feasible. All included trials were published in English, and there were only two trials either declaring no commercial funding, <a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a>, or providing no statement about funding in the manuscript, <a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a>, therefore sensitivity analyses according to language of publication or excluding trials funded by a pharmaceutical company were not meaningful. </p> <p>It was not feasible to combine results from cross‐over trials and trials with parallel design, as cross‐over trials were available only for the comparison NNS versus sugar, and trials with a parallel design were only available for the comparisons NNS versus placebo and NNS versus another type of sweetener. We performed sensitivity analyses to investigate the impact of assumed correlation coefficients for the imputation of the standard deviation of difference in cross‐over trials with mean difference as the measure of treatment effect (<a href="./references#CD012885-fig-0033" title="">Analysis 4.1</a>; <a href="./references#CD012885-fig-0034" title="">Analysis 4.2</a>; <a href="./references#CD012885-fig-0035" title="">Analysis 4.3</a>; <a href="./references#CD012885-fig-0036" title="">Analysis 4.4</a>; <a href="./references#CD012885-fig-0037" title="">Analysis 4.5</a>; <a href="./references#CD012885-fig-0038" title="">Analysis 4.6</a>; <a href="./references#CD012885-fig-0039" title="">Analysis 4.7</a>; <a href="./references#CD012885-fig-0040" title="">Analysis 4.8</a>; <a href="./references#CD012885-fig-0041" title="">Analysis 4.9</a>), and concluded that the assumed correlation coefficient has no relevant effect on the overall effect estimate. </p> </section> <section id="CD012885-sec-0129"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not use funnel plots due to the limited number of trials (N = 3 for the comparison NNS versus sugar, N = 5 for the comparison NNS versus placebo, and only one trial for the comparison NNS versus another type of sweetener). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD012885-sec-0130" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD012885-sec-0130"></div> <section id="CD012885-sec-0131"> <h3 class="title" id="CD012885-sec-0131">Summary of main results</h3> <p>This Cochrane Review investigated the health effects of NNS compared with any other type of dietary intervention in people with type 1 or type 2 diabetes. We included nine trials with a total of 979 randomised participants. We judged all trials to have unclear or high risk of bias in one or more ’Risk of bias’ domains. We found no evidence of benefit or harm on patient‐important outcomes. Evidence on the use of NNS showed neither clear benefit nor harm for HbA1c, body weight, and adverse events for the comparisons NNS versus sugar and NNS versus placebo (very low‐certainty evidence). For the comparison NNS versus a nutritive, low‐calorie sweetener (tagatose), there was a small benefit for HbA1c in favour of the nutritive, low‐calorie sweetener, based on very low‐certainty evidence and which we judged as clinically irrelevant. </p> </section> <section id="CD012885-sec-0132"> <h3 class="title" id="CD012885-sec-0132">Overall completeness and applicability of evidence</h3> <p>The evidence for health benefits or harms related to NNS consumption in diabetes mellitus as compared to a diet without NNS, a diet containing sugar, or a diet containing a nutritive, low‐calorie sweetener, is incomplete. We included nine completed trials involving adult participants with either type 1 or type 2 diabetes. </p> <p>For the comparison NNS versus sugar, there were only three small cross‐over trials available, which contributed data for meta‐analyses for HbA1c (three trials), body weight (three trials), total cholesterol (three trials), HDL cholesterol (three trials), triglycerides (three trials), and fasting blood glucose levels (two trials). For the outcomes LDL cholesterol, postprandial blood glucose levels, and serum insulin, data were available from only one trial. Consequently, there remains a paucity of evidence regarding the effects of these interventions in diabetes on medium‐ or longer‐term health. </p> <p>For the comparison NNS versus placebo, five trials were available, all with a parallel study design. Three of these trials were small, with fewer than 100 participants, whilst the other two trials included between 100 and 200 participants. These trials contributed data for meta‐analyses for HbA1c (four trials), body weight (two trials), total cholesterol (three trials), HDL cholesterol (two trials), LDL cholesterol (two trials), triglycerides (two trials), fasting blood glucose levels (five trials), serum insulin levels (two trials), and adverse events (three trials). For the outcomes BMI and postprandial blood glucose levels, data were available from only one trial. </p> <p>For the comparison NNS versus a nutritive sweetener, only one trial was available, which provided data on the outcomes HbA1c, lipid profile, and fasting glucose. </p> <p>There were no data from included trials with regard to health‐related quality of life, diabetes complications, all‐cause mortality, or socioeconomic effects. </p> <p>Our ability to draw firm conclusions was further limited by notable variations in the characteristics of the interventions assessed (i.e. the different types of NNS used in different trials) and participants included in the trials (i.e. participants with type 1 or type 2 diabetes, with or without different comorbidities). Whilst we chose to combine trials with type 1 and type 2 diabetes participants in one comparison, and attempted to explore variation through subgroup analyses, our ability to do this was limited because of the low number of trials in total. Furthermore, the types of NNS used in the included trials varied widely amongst trials, but due to the low number of included trials we were also not able to conduct a subgroup analysis by type of NNS. </p> <p>With regard to applicability, eight of the nine included trials were conducted in upper‐middle‐ or high‐income countries. This likely limits the generalisability of the findings to other countries, particularly low‐resource settings. Furthermore, in most of the included trials diagnostic criteria for diabetes were not specified, which may limit the interpretation of data. </p> </section> <section id="CD012885-sec-0133"> <h3 class="title" id="CD012885-sec-0133">Quality of the evidence</h3> <p>For all outcomes evaluated using GRADE, we judged the evidence to be of very low‐certainty for all three comparisons (NNS versus sugar, placebo, or a nutritive, low‐calorie sweetener). The evidence was downgraded primarily due to design limitations (risk of bias) and imprecision (small sample sizes and low number of included studies). </p> </section> <section id="CD012885-sec-0134"> <h3 class="title" id="CD012885-sec-0134">Potential biases in the review process</h3> <p>The search for trials in this area was performed using a broad search strategy, by searching in both electronic databases and trials registries, without applying restrictions, such as based on language. It is unlikely that trials that have been conducted and published have been missed; however, unpublished trials, or ongoing trials not registered in clinical trials registries could be missing. Should such trials be identified, we will include them in future updates of the review. </p> <p>We aimed to reduce bias wherever possible by having at least two review authors work independently on trial selection, data extraction, and 'Risk of bias' and GRADE assessments. </p> <p>We were not able to explore the potential for publication bias using funnel plots, since there were no outcomes of interest with 10 or more trials included in meta‐analyses. </p> </section> <section id="CD012885-sec-0135"> <h3 class="title" id="CD012885-sec-0135">Agreements and disagreements with other studies or reviews</h3> <p>In our search for additional trials we checked other systematic reviews and meta‐analyses. Most of these assessed the use of NNS compared to another dietary intervention in healthy or general populations (<a href="./references#CD012885-bbs2-0099" title="AzadMB , Abou-SettaAM , ChauhanBF , RabbaniR , LysJ , CopsteinL , et al. Nonnutritive sweeteners and cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials and prospective cohort studies. CMAJ : Canadian Medical Association Journal2017;189(28):E929-39.">Azad 2017</a>; <a href="./references#CD012885-bbs2-0160" title="ToewsI , LohnerS , Küllenberg de GaudryD , SommerH , MeerpohlJJ . Association between intake of non-sugar sweeteners and health outcomes: systematic review and meta-analyses of randomised and non-randomised controlled trials and observational studies. BMJ2019;364:k4718.">Toews 2019</a>), whilst the number of systematic reviews including participants with diabetes was limited. </p> <p>One systematic review collecting evidence on the health effects of NNS in diabetes included not only medium‐ and long‐term outcomes, but also short‐term trials with an intervention duration of four weeks or less (<a href="./references#CD012885-bbs2-0158" title="Timpe BehnenEM , FergusonMC , CarlsonA . Do sugar substitutes have any impact on glycemic control in patients with diabetes?Journal of Pharmacy Technology2013;29:61-5.">Timpe Behnen 2013</a>). After narratively summarising their findings, the authors of this systematic review concluded that "nonnutritive sweeteners do not appear to affect glycemic control in patients with diabetes". It should be noted that this systematic review included only studies published in English and considered only NNS available in the USA. To our knowledge, our review is the first systematic review attempting to address patient‐important outcomes, such as health‐related quality of life or socioeconomic effects. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD012885-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Trial flow diagram." data-id="CD012885-fig-0001" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Trial flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials)." data-id="CD012885-fig-0002" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included trials (blank cells indicate that the particular outcome was not measured in some trials). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials)" data-id="CD012885-fig-0003" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included trial (blank cells indicate that the particular outcome was not measured in some trials) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 NNS versus placebo, outcome: 2.1 HbA1c (%)." data-id="CD012885-fig-0004" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 NNS versus placebo, outcome: 2.1 HbA1c (%).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 NNS versus placebo, outcome: 2.2 Body weight (kg)." data-id="CD012885-fig-0005" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 NNS versus placebo, outcome: 2.2 Body weight (kg).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 2 NNS versus placebo, outcome: 2.3 Adverse events (n/N)." data-id="CD012885-fig-0006" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of comparison: 2 NNS versus placebo, outcome: 2.3 Adverse events (n/N).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-FIG-06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 1: HbA1c (%)" data-id="CD012885-fig-0007" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 1: HbA1c (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 2: Body weight (kg)" data-id="CD012885-fig-0008" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 2: Body weight (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 3: Total cholesterol (mg/dL)" data-id="CD012885-fig-0009" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 3: Total cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 4: HDL cholesterol (mg/dL)" data-id="CD012885-fig-0010" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 4: HDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 5: LDL cholesterol (mg/dL)" data-id="CD012885-fig-0011" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 5: LDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 6: Triglycerides (mg/dL)" data-id="CD012885-fig-0012" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 6: Triglycerides (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 7: Fasting blood glucose levels (mg/dL)" data-id="CD012885-fig-0013" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 7: Fasting blood glucose levels (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 8: Postprandial blood glucose levels (mg/dL)" data-id="CD012885-fig-0014" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 8: Postprandial blood glucose levels (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-001.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: NNS versus sugar, Outcome 9: Serum insulin (microunits/mL)" data-id="CD012885-fig-0015" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-001.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1: NNS versus sugar, Outcome 9: Serum insulin (microunits/mL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-001.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 1: HbA1c (%)" data-id="CD012885-fig-0016" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 1: HbA1c (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 2: Body weight (kg)" data-id="CD012885-fig-0017" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 2: Body weight (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 3: Adverse events (n/N)" data-id="CD012885-fig-0018" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 3: Adverse events (n/N)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 4: BMI (kg/m²)" data-id="CD012885-fig-0019" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 4: BMI (kg/m²)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 5: Total cholesterol (mg/dL)" data-id="CD012885-fig-0020" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 5: Total cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 6: HDL cholesterol (mg/dL)" data-id="CD012885-fig-0021" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 6: HDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 7: LDL cholesterol (mg/dL)" data-id="CD012885-fig-0022" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 7: LDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 8: Triglycerides (mg/dL)" data-id="CD012885-fig-0023" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 8: Triglycerides (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 9: Fasting blood glucose levels (mg/dL)" data-id="CD012885-fig-0024" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 9: Fasting blood glucose levels (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.09.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.10" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 10: Postprandial blood glucose levels (mg/dL)" data-id="CD012885-fig-0025" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.10.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 10: Postprandial blood glucose levels (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.10.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-002.11" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: NNS versus placebo, Outcome 11: Serum insulin (microunits/mL)" data-id="CD012885-fig-0026" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.11.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-002.11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2: NNS versus placebo, Outcome 11: Serum insulin (microunits/mL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-002.11.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-003.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NNS versus another type of sweetener, Outcome 1: HbA1c (%)" data-id="CD012885-fig-0027" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-003.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3: NNS versus another type of sweetener, Outcome 1: HbA1c (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-003.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NNS versus another type of sweetener, Outcome 2: Total cholesterol (mg/dL)" data-id="CD012885-fig-0028" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-003.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3: NNS versus another type of sweetener, Outcome 2: Total cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-003.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NNS versus another type of sweetener, Outcome 3: HDL cholesterol (mg/dL)" data-id="CD012885-fig-0029" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-003.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3: NNS versus another type of sweetener, Outcome 3: HDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-003.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NNS versus another type of sweetener, Outcome 4: LDL cholesterol (mg/dL)" data-id="CD012885-fig-0030" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-003.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3: NNS versus another type of sweetener, Outcome 4: LDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-003.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NNS versus another type of sweetener, Outcome 5: Triglycerides (mg/dL)" data-id="CD012885-fig-0031" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-003.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3: NNS versus another type of sweetener, Outcome 5: Triglycerides (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-003.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 3: NNS versus another type of sweetener, Outcome 6: Fasting glucose (mg/dL)" data-id="CD012885-fig-0032" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-003.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3: NNS versus another type of sweetener, Outcome 6: Fasting glucose (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-003.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 1: HbA1c (%)" data-id="CD012885-fig-0033" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 1: HbA1c (%)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 2: Body weight (kg)" data-id="CD012885-fig-0034" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 2: Body weight (kg)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 3: Total cholesterol (mg/dL)" data-id="CD012885-fig-0035" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 3: Total cholesterol (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.04" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 4: HDL cholesterol (mg/dL)" data-id="CD012885-fig-0036" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.04.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 4: HDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.04.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.05" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 5: LDL cholesterol (mg/dL)" data-id="CD012885-fig-0037" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.05.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 5: LDL cholesterol (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.05.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.06" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 6: Triglycerides (mg/dL)" data-id="CD012885-fig-0038" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.06.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 6: Triglycerides (mg/dL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.06.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.07" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 7: Fasting blood glucose levels (mg/dL)" data-id="CD012885-fig-0039" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.07.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 7: Fasting blood glucose levels (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.07.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.08" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 8: Postprandial blood glucose levels (mg/dL)" data-id="CD012885-fig-0040" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.08.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 8: Postprandial blood glucose levels (mg/dL) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.08.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD012885-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/urn:x-wiley:14651858:media:CD012885:CD012885-CMP-004.09" target="_blank"><b></b></a></p> </div><img alt="Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 9: Serum insulin (microunits/mL)" data-id="CD012885-fig-0041" src="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.09.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_t/tCD012885-CMP-004.09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4: Sensitivity analysis: NNS versus sugar, Outcome 9: Serum insulin (microunits/mL)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/media/CDSR/CD012885/image_n/nCD012885-CMP-004.09.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD012885-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Non‐nutritive sweeteners for diabetes mellitus</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Non‐nutritive sweeteners compared with sucrose, placebo, or a nutritive, low‐calorie sweetener for diabetes mellitus</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient:</b> people with diabetes mellitus </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> non‐nutritive sweeteners (aspartame, rebaudioside A, saccharin, sodium‐cyclamate, sucralose, steviol glycoside) </p> <p><b>Comparison:</b> sucrose; placebo; nutritive, low‐calorie sweetener (tagatose) </p> </td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes/Comparisions</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comparator<br/>(sucrose; placebo; nutritive, low‐calorie sweetener)</b> </p> </th> <th align="left" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Non‐nutritive sweeteners<br/>(aspartame, rebaudioside A, saccharin, sodium‐cyclamate, sucralose, steviol glycoside)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Health‐related quality of life</b> </p> </th> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Diabetes complications</b> </p> </th> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>All‐cause mortality</b> </p> </th> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Non‐serious adverse events (N)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus sugar</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus placebo</b> </p> <p>NNS: aspartame, rebaudioside A, steviol glycoside</p> <p>Follow‐up: 16 to 18 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>356 per 1000</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>278 per 1000</b> (139 to 555) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.78</b> (0.39 to 1.56) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>a</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus nutritive, low‐calorie sweetener</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>HbA1c (%)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus sugar</b> </p> <p>NNS: aspartame, saccharin, sodium‐cyclamate</p> <p>Follow‐up: 4 to 6 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c ranged across control groups from <b>6.8% to 7.5%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the NNS group was <b>0.4% higher</b> (0.5% lower to 1.2% higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>b</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus placebo</b> </p> <p>NNS: aspartame, rebaudioside A, steviol glycoside</p> <p>Follow‐up: 13 to 16 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final HbA1c ranged across control groups from <b>7.3% to 11.4%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the NNS and placebo groups <b>did not differ</b> (MD 0%, −0.1% lower to 0.1% higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>360 (4)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>c</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>The 95% prediction interval ranged between −0.3% and 0.3%</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus nutritive, low‐calorie sweetener (tagatose)</b> </p> <p>NNS: sucralose</p> <p>Follow‐up: 16 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the control group was <b>7.3%</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean HbA1c in the NNS group was <b>0.3% higher</b> (0.1% higher to 0.4% higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>354 (1)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>d</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="7" rowspan="1" scope="col" valign="top"> <p><b>Body weight (kg)</b> </p> </th> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus sugar</b> </p> <p>NNS: aspartame, saccharin, sodium‐cyclamate</p> <p>Follow‐up: 4 to 6 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the control groups was <b>66.8 kg to 75.9 kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the intervention groups was <b>0.1 kg lower</b> (2.7 kg lower to 2.6 kg higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (3)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>e</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus placebo</b> </p> <p>NNS: aspartame, rebaudioside A</p> <p>Follow‐up: 12 to 16 weeks</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean final body weight ranged across control groups from to <b>79.4 to 98.4 kg</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean body weight in the intervention groups was <b>0.2 kg lower</b> (1 kg lower to 0.6 kg higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184 (2)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<sup>f</sup><br/><b>very low</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>NNS versus nutritive, low‐calorie sweetener</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Socioeconomic effects</b> </p> </th> <td align="" class="table-tint table-highlight" colspan="5" rowspan="1" valign="top"> <p><b>Not reported</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across trials) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/><b>CI:</b> confidence interval; <b>HbA1c:</b> glycosylated haemoglobin A1c; <b>MD:</b> mean difference; <b>NNS:</b> non‐nutritive sweetener; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> </p> <p><b>High certainty:</b> we are very confident that the true effect lies close to that of the estimate of the effect.<br/><b>Moderate certainty:</b> we are moderately confident in the effect estimate; the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different.<br/><b>Low certainty:</b> our confidence in the effect estimate is limited; the true effect may be substantially different from the estimate of the effect.<br/><b>Very low certainty:</b> we have very little confidence in the effect estimate; the true effect is likely to be substantially different from the estimate of effect. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded by one level because of inconsistency (no consistent direction of effect) and two levels because of serious imprecision (CI consistent with benefit and harm, small sample size, and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0159">Appendix 18</a>.<br/><sup>b</sup>Downgraded by one level because of inconsistency (point estimates varied widely, not all CIs overlapped, no consistent direction of effect); one level because of indirectness (surrogate outcome, insufficient time frame); and one level because of serious imprecision (CI consistent with benefit and harm, small sample size, and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0158">Appendix 17</a>.<br/><sup>c</sup>Downgraded by one level because of indirectness (surrogate outcome) and two levels because of serious imprecision (small sample size and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0159">Appendix 18</a>.<br/><sup>d</sup>Downgraded by one level because of risk of bias (attrition bias and selective reporting); one level because of indirectness (surrogate outcome); and one level because of imprecision (small number of included studies) ‐ see <a href="./appendices#CD012885-sec-0160">Appendix 19</a>.<br/><sup>e</sup>Downgraded by one level because of inconsistency (no consistent direction of effect) and two levels because of serious imprecision (CI consistent with benefit and harm, small sample size, and small number of studies) ‐ see <a href="./appendices#CD012885-sec-0158">Appendix 17</a>.<br/><sup>f</sup>Downgraded by one level because of risk of bias (selective reporting) and two levels because of serious imprecision (small sample size and small number of included studies) ‐ see <a href="./appendices#CD012885-sec-0159">Appendix 18</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Non‐nutritive sweeteners for diabetes mellitus</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012885-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Acceptable daily intake levels of non‐nutritive sweeteners as defined by regulatory bodies</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sweetener</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>FDA (mg/kg body weight) (</b><a href="./references#CD012885-bbs2-0117" title="US Food and Drug Administration. High-intensity sweeteners. www.fda.gov/food/ingredientspackaginglabeling/foodadditivesingredients/ucm397716.htm (accessed 26 January 2017)."><b>FDA 2015a</b> </a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>SCF/EFSA (mg/kg body weight) (</b><a href="./references#CD012885-bbs2-0145" title="MortensenA . Sweeteners permitted in the European Union: safety aspects. Scandinavian Journal of Food and Nutrition2006;50(3):104-16."><b>Mortensen 2006</b> </a><b>)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>JECFA (mg/kg body weight) (</b><a href="./references#CD012885-bbs2-0136" title="World Health Organization. Evaluations of the Joint FAO/WHO expert committee on food additives. apps.who.int/food-additives-contaminants-jecfa-database/search.aspx?fcc=1 (accessed 26 January 2017)."><b>JECFA 2010</b> </a><b>)</b> </p> </th> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ACE‐K</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Advantame</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aspartame</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cyclamate</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not approved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Luo han guo fruit extracts</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neohesperidine DC</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not approved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not evaluated</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Neotame</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Saccharin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sucralose</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Steviol glycosides</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Thaumatin</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not approved</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not specified</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><b>ACE‐K</b> : acesulfame potassium; <b>DC</b> : dihydrochalcone; <b>EFSA</b> : European Food Safety Authority;<b>FDA</b> : US Food and Drug Administration; <b>JECFA</b> : Joint FAO/WHO Expert Committee on Food Additives; <b>SCF</b>: Scientific Committee on Food (European Commission). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Acceptable daily intake levels of non‐nutritive sweeteners as defined by regulatory bodies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD012885-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of trial populations</span></div> <tbody> <tr> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Trial ID (trial design)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Intervention(s) and comparator(s)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Description of power and sample size calculation</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Screened/eligible (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Analysed (primary outcome) (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Finishing trial (N)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Randomised finishing trial (%)</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Follow‐up</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0005" title="CTRI/2009/091/000536. Effects of Naturlose (Tagatose) on blood sugar control and safety of Naturlose over one year in subjects with type 2 diabetes under diet control and exercise. apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2009/091/000536 (first received 17 April 2007; last updated 21 May 2019). EnsorM , BanfieldAM , SmithRR , WilliamsJ , LodderRA . Safety and efficacy of D-tagatose in glycemic control in subjects with type 2 diabetes. Journal of Endocrinology, Diabetes and Obesity2015;3:1. NCT00955747. Naturlose (D-Tagatose) efficacy evaluation trial (NEET). clinicaltrials.gov/ct2/show/study/NCT00955747 (first received 10 August 2009; last updated 15 November 2014). ">Ensor 2015</a> (parallel RCT) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: Splenda 1.5 g 3 times a day, dissolved in 125 to 250 mL water</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: D‐tagatose 15 g 3 times a day, dissolved in 125 to 250 mL water</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <td align="left" class="headercell" colspan="3" rowspan="1" valign="top"></td> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>494</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>356</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>204</b> </p> </th> <th align="left" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>41.3</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0001" title="BarriocanalLA , PalaciosM , BenitezG , BenitezS , JimenezJT , JimenezN , et al. Apparent lack of pharmacological effect of steviol glycosides used as sweeteners in humans. A pilot study of repeated exposures in some normotensive and hypotensive individuals and in type 1 and type 2 diabetics. Regulatory Toxicology and Pharmacology : RTP2008;51(1):37-41. ">Barriocanal 2008</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: steviol glycoside capsules 250 mg 3 times a day (92% purity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"Power analysis were also conducted to determine whether the samples were large enough to allow for the detection of a clinically significant change between baseline and post treatment levels within the control and treatment groups. A clinically significant difference was defined based on the range of 'normal' values for each of the parameters considered." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 + 15<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>3 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo capsules 3 times a day</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8 + 15<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23<sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>53</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>46</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>46</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>86.8</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0007" title="MakiKC , CurryLL , ReevesMS , TothPD , McKenneyJM , FarmerMV , et al. Chronic consumption of rebaudioside A, a steviol glycoside, in men and women with type 2 diabetes mellitus. Food and Chemical Toxicology2008;46 Suppl 7:47-53. ">Maki 2008</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: rebaudioside A 250 mg 4 times a day in capsules (97% purity)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The study was designed to provide 90% power (α = 0.05, two‐sided) to detect a 0.5% difference in HbA1c response between treatment groups, assuming a standard deviation of 0.8%." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>16 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo capsules 4 times a day (microcrystalline cellulose)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.5</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>122</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>122</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>116</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>95.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0006" title="GrotzVL , HenryRR , McGillJB , PrinceMJ , ShamoonH , TroutJR , et al. Lack of effect of sucralose on glucose homeostasis in subjects with type 2 diabetes. Journal of the American Dietetic Association2003;103(12):1607-12. ">Grotz 2003</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sucralose 667 mg daily in capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>"The number of subjects was based on achieving at least 90% power to detect a 0.6 treatment group difference in percent HbA1c change from baseline. Post‐study analysis showed that the study provided more than 99.99% power to detect this difference, and more than 90% to detect a difference of 0.3." </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>17 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo (cellulose) capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68<sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.2</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>136</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>133<sup>c</sup> </b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>128</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>94.1</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0003" title="ColagiuriS , MillerJJ , EdwardsRA . Metabolic effects of adding sucrose and aspartame to the diet of subjects with noninsulin-dependent diabetes mellitus. American Journal of Clinical Nutrition1989;50(3):474-8. ">Colagiuri 1989</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: aspartame 162 mg daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: sucrose 45 g daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>9</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0004" title="CooperPL , WahlqvistML , SimpsonRW . Sucrose versus saccharin as an added sweetener in non-insulin-dependent diabetes: short- and medium-term metabolic effects. Diabetic Medicine1988;5(7):676-80. ">Cooper 1988</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: saccharin and starch 30 g daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>6 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: sucrose 28 g daily, added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>17</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0002" title="ChantelauEA , GosseringerG , SonnenbergGE , BergerM . Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia1985;28(4):204-7. ">Chantelau 1985</a> </p> <p>(cross‐over RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: sodium‐cyclamate, ad libitum (348 ± 270 mg/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>4 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: sucrose, ad libitum (24 ± 13 g/day)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>10</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>100</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0008" title="NehrlingJK , KobeP , McLaneMP , OlsonRE , KamathS , HorwitzDL . Aspartame use by persons with diabetes. Diabetes Care1985;8(5):415-7. ">Nehrling 1985</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: aspartame 2.7 g daily, in capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>63</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96.7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>18 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: placebo (cornstarch) 1.8 g daily in capsules</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>63</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>62</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>98.4</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><a href="./references#CD012885-bbs2-0009" title="SternSB , BleicherSJ , FloresA , GombosG , RecitasD , ShuJ . Administration of aspartame in non-insulin-dependent diabetics. Journal of Toxicology &amp; Environmental Health1976;2(2):429-39. ">Stern 1976</a> </p> <p>(parallel RCT)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>I: aspartame 300 mg capsules, 2 capsules 3 times daily added to the usual diet</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p>13 weeks</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>C: matched placebo</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>‐</p> </td> </tr> <tr> <th align="right" class="headercell" colspan="3" rowspan="1" scope="col" valign="top"> <p><b>total:</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>75</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>‐</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>69</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>92</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Grand total</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>437</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>364</b><sup>e</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="2" rowspan="3" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All comparators</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>432</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>333</b><sup>e</sup> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>All interventions and comparators</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>979</b><sup>d</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>661</b><sup>e</sup> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="9"> <div class="table-footnote"> <p>‐: denotes not reported</p> <p><b>C</b> : comparator; <b>HbA1c</b> : glycosylated haemoglobin A1c; <b>I</b> : intervention; <b>RCT</b>: randomised controlled trial. </p> <p><sup>a</sup>We provided numbers for the intention‐to‐treat analysis. Authors also performed a per‐protocol analysis, with 119 participants in the Splenda and 85 in the tagatose group.<br/><sup>b</sup>This trial included participants with type 1 and type 2 diabetes and participants without diabetes. We only reported on participants with type 1 and type 2 diabetes.<br/><sup>c</sup>For the two primary outcomes of the trial, the number of participants included in the analyses was reported only for fasting plasma glucose, but not for HbA1c values.<br/><sup>d</sup>Not all trials described the number of participants randomised to each intervention/comparator group, therefore the numbers do not add up correctly.<br/><sup>e</sup>There are cross‐over trials amongst the included trials, therefore the numbers do not add up correctly. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Overview of trial populations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/full#CD012885-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012885-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NNS versus sugar</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.35 [‐0.54, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐2.72, 2.59]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Total cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.77 [‐11.10, 9.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.4 HDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐5.59, 3.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.5 LDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.6 Triglycerides (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.52 [‐14.96, 11.91]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.7 Fasting blood glucose levels (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.02 [‐28.31, 18.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.8 Postprandial blood glucose levels (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.9 Serum insulin (microunits/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">NNS versus sugar</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012885-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NNS versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.00 [‐0.13, 0.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.1 Studies with final value scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.51, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1.2 Studies with change‐from‐baseline scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>252</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.13, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.2 Body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>184</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.19 [‐1.01, 0.63]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.1 Studies with final value scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>62</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐6.82, 8.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2.2 Studies with change‐from‐baseline scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐1.02, 0.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.3 Adverse events (n/N) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.39, 1.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.4 BMI (kg/m²) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.5 Total cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>228</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.99 [‐4.82, 8.80]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.1 Studies with final value scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.75 [‐10.83, 18.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.5.2 Studies with change‐from‐baseline scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.50 [‐6.20, 9.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.6 HDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐2.17, 1.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.1 Studies with final value score</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.32 [‐4.99, 4.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.6.2 Studies with change‐from‐baseline scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.40 [‐2.32, 1.52]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.7 LDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>168</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.09 [‐2.90, 9.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.1 Studies with final values</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [‐11.45, 13.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.7.2 Studies with change‐from‐baseline scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.70 [‐3.13, 10.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.8 Triglycerides (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.8.1 Studies with final value scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>106</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>18.47 [‐6.78, 43.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.9 Fasting blood glucose levels (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>384</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.24 [‐11.60, 16.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.1 Studies with final value scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>251</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.07 [‐23.65, 25.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.9.2 Studies with change‐from‐baseline scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>133</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.96 [‐7.30, 15.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.10 Postprandial blood glucose levels (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.10.1 Studies with final value scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.11 Serum insulin (microunits/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>152</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.51 [‐5.39, 0.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.1 Studies with final value scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>30</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.70 [‐11.13, 3.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.11.2 Studies with change‐from‐baseline scores</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>122</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.30 [‐5.42, 0.82]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">NNS versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012885-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NNS versus another type of sweetener</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.2 Total cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.3 HDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.4 LDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.5 Triglycerides (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3.6 Fasting glucose (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">NNS versus another type of sweetener</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD012885-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis: NNS versus sugar</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.1 HbA1c (%) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.36 [‐0.52, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [‐0.57, 1.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.2 Body weight (kg) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐3.81, 3.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐1.75, 1.61]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.3 Total cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.87 [‐15.35, 13.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.38 [‐10.21, 7.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.4 HDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.10 [‐7.40, 5.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.4.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.06 [‐3.98, 1.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.5 LDL cholesterol (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.5.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.6 Triglycerides (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.53 [‐19.91, 16.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.6.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.49 [‐10.75, 7.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.7 Fasting blood glucose levels (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.01 [‐37.78, 27.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.7.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐5.05 [‐19.99, 9.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.8 Postprandial blood glucose levels (mg/dL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.8.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4.9 Serum insulin (microunits/mL) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.1 Correlation coefficient: 0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.9.2 Correlation coefficient: 0.8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Totals not selected</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Sensitivity analysis: NNS versus sugar</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD012885.pub2/references#CD012885-tbl-0007">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD012885.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD012885-note-0006">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD012885-note-0016">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD012885-note-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD012885-note-0015">Français</a> </li> <li class="section-language"> <a class="" href="ja#CD012885-note-0013">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD012885-note-0010">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD012885-note-0012">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD012885-note-0009">Русский</a> </li> <li class="section-language"> <a class="" href="th#CD012885-note-0011">ภาษาไทย</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD012885-note-0007">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD012885-note-0008">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012885\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012885\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012885\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD012885\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD012885\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=23LRTUA6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012885.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD012885.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD012885.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD012885.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD012885.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717306939"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012885.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717306943"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD012885.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918db4b81af59365',t:'MTc0MDcxNzMwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 